 
 
       
 
Immune  
Tolerance  
Network  
 
   
Preserving Beta -Cell Function with Tocilizumab in New -onset 
Type 1 Diabetes  
 Protocol ITN0 58AI 
 Version V6.0 (June 13, 2018)    
 
Protocol Co -Chair 
 
 
 
 
    
   Protocol Co-Chair 
 
 
 
 
 
  
ITN Clinical Trial Physician  
 
 
 
 
 
 
 
  NIAID Medical Monitor  
 
  
  
 
  
 
 
 
  
 
 
ITN Clinical Operations Manager  
 
 
 
 
 
 
 
  
 
 
 
 
 NIAID Project Manager  
 
 
  
  
 
 
 
  
  
 

Immune Tolerance Network  CONFIDENTIAL  Page 2 
Protocol ITN058AI: Greenbaum  Version 6.[ADDRESS_219010] udy staff, and applicable ethics committees or institutional review 
boards.  It is understood that the contents of this document will not be disclosed to others without 
written authorization from ITN and NIAID unless it is necessary to obtain informed cons ent from 
potential study participants . 

Immune Tolerance Network  CONFIDENTIAL  Page 3 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   Protocol Approval  
 Protocol:  ITN058AI Protocol Version :  V6.0 
Dated:  June 13, 2018 
US IND # 117725 Protocol Co-Chairs:   
 
Title:     Preserving Beta -Cell Function with Tocilizumab in New -onset Type [ADDRESS_219011] version.  I understand it, and I will 
work according to the principles of good clinical practice (GCP) as described in the US Code of 
Federal R egulations (CFR)‚Äî45 CFR part 46 and  21 CFR parts 50, 56, and 312, and in the 
International Conference on Harmonization (ICH) document Guidance for Industry: E6 Good 
Clinical Practice: Consolidated Guidance  dated April 1996.  Further, I will conduct the study in 
keepi[INVESTIGATOR_80860].  
 
As the principal investigator, I agree to carry out the study by [CONTACT_93216]. 
 
 
 
_____________________________ ___________ __                                        
Principal Investigator                        (Print)                     
 
 
__________________________________________          _________________  
Principal Investigator                        (Sign)                      Date 
 

Immune Tolerance Network  CONFIDENTIAL  Page 4 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   Table of Contents  
1. BACKGROUND AND RATIO NALE ................................ ................................ ................  14 
1.1 BACKGROUND AND SCIEN TIFIC RATIONALE  ................................ ..........................  14 
1.1.1 Type 1 diabetes (T1D)  ................................ ................................ ................................ ...............  14 
1.1.2 Tocilizumab  ................................ ................................ ................................ ...............................  16 
1.2 PRECLINICAL AND CLIN ICAL EXPERIENCE ................................ ..............................  18 
1.2.1 Preclinical Studies  ................................ ................................ ................................ .....................  18 
1.2.2 Clinical Studies  ................................ ................................ ................................ ..........................  18 
1.3 SUMMARY OF KNOWN AND  POTENTIAL RISKS AND  BENEFITS FOR HUMAN 
PARTICIPANTS  ................................ ................................ ................................ ............  23 
1.3.1 Overview  ................................ ................................ ................................ ................................ ... 23 
1.3.2 Risks ................................ ................................ ................................ ................................ .......... 24 
1.3.3 Potential Risks and Benefits of Trial Participation for Children  ................................ ...............  27 
1.3.4 Benefits of Trial Participation  ................................ ................................ ................................ ... 27 
2. OBJECTIVES  ................................ ................................ ................................ ....................  28 
2.1 PRIMARY OBJECTIVE  ................................ ................................ ................................ .. 28 
2.2 SECONDARY OBJECTIVES  ................................ ................................ ..........................  28 
2.3 EXPLORATORY OBJECTIV ES ................................ ................................ ......................  28 
3. STUDY DESIGN ................................ ................................ ................................ ................  29 
3.1 DESCRIPTION  ................................ ................................ ................................ ...............  29 
3.2 STUDY DU RATION  ................................ ................................ ................................ ....... 30 
3.3 STUDY ENDPOINTS  ................................ ................................ ................................ ...... 31 
3.3.1 Primary Endpoint  ................................ ................................ ................................ ......................  31 
3.3.2 Secondary Endpoints  ................................ ................................ ................................ .................  31 
3.3.3 Exploratory Endpoints  ................................ ................................ ................................ ...............  31 
3.4 RATIONALE FOR SELECTION OF DRU G, ROUTE, DOSE, AND REGIMEN  ................  31 
3.5 PREMATURE TERMINATIO N OR SUSPENSION OF T HE TRIAL  ................................ . 32 
3.5.1 Ongoing Review  ................................ ................................ ................................ ........................  32 
3.5.2 Stoppi[INVESTIGATOR_1869]  ................................ ................................ ................................ ..........................  33 
4. ELIGIBILITY  ................................ ................................ ................................ ...................  33 
4.1 INCLUSION CRITERIA  ................................ ................................ ................................ .. 33 
4.2 EXCLUSION CRITERIA  ................................ ................................ ................................ . 34 
4.3 PREMATURE TERMINATIO N OF A PARTICIPANT F ROM THE STUDY  .....................  35 
Immune Tolerance Network  CONFIDENTIAL  Page 5 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   5. STUDY MEDICATIONS  ................................ ................................ ................................ ... 35 
5.1 INVESTIGATIONAL MEDICATI ON ................................ ................................ ..............  35 
5.1.1 Formulation and Packaging  ................................ ................................ ................................ ....... 36 
5.1.2 Reconstitution  ................................ ................................ ................................ ............................  36 
5.1.3 Dosage, Preparation, and Administration  ................................ ................................ ..................  36 
5.2 DOSE MODIFICATION AN D MANAGEMENT OF ADVE RSE EVENTS  ........................  37 
5.2.1 Overview  ................................ ................................ ................................ ................................ ... 37 
5.2.2 Hematolo gic Abnormalities and Bleeding Events  ................................ ................................ ..... 37 
5.2.3 Blood Chemistry Abnormalities  ................................ ................................ ................................  37 
5.2.4 Infections  ................................ ................................ ................................ ................................ ... 38 
5.2.5 Elevated Lipi[INVESTIGATOR_805]  ................................ ................................ ................................ ..........................  39 
5.2.6 Hypersensitivity or Anaphylaxis  ................................ ................................ ...............................  39 
5.3 DISCONTINUATION OF S TUDY MEDICATION IN A N INDIVIDUAL PARTICI PANT  . 39 
5.4 CONCOMITANT MEDICATIONS  ................................ ................................ ..................  40 
5.4.1 Prohibited Medications  ................................ ................................ ................................ .............. 40 
5.5 DRUG ACCOUNTABILITY ................................ ................................ ............................  40 
5.6 ASSESSMENT OF COMPLI ANCE WITH STUDY MEDI CATION  ................................ .. 41 
6. STUDY PROCEDURES  ................................ ................................ ................................ .... 41 
6.1 INTENSIVE DIABETES M ANAGEMENT  ................................ ................................ ...... 41 
6.2 VISIT WINDOWS  ................................ ................................ ................................ ...........  41 
6.2.1 Scheduled Visits  ................................ ................................ ................................ ........................  41 
6.3 RANDOMIZATION, MASKI NG, AND UNMASKING  ................................ ....................  41 
6.3.1 Randomization  ................................ ................................ ................................ ...........................  41 
6.3.2 Masking to treatment assignment  ................................ ................................ ..............................  42 
6.3.3 Unmasking ................................ ................................ ................................ ................................ . 42 
6.4 GENERAL ASSESSMENTS  ................................ ................................ ............................  42 
6.5 CLINICAL LABORATORY ASSESSMENTS  ................................ ................................ .. 43 
6.6 PHARMACOKINETIC ASSE SSMENTS  ................................ ................................ ..........  44 
6.7 METABOLIC ASSESSMENT S ................................ ................................ .......................  45 
6.8 MECHANISTIC ASSESSME NTS ................................ ................................ ....................  45 
7. TOLERANCE ASSAYS  ................................ ................................ ................................ ..... 45 
7.1 MECHANISTIC HYPOTHES IS ................................ ................................ .......................  45 
7.2 RETENTION OF SAMPLES  ................................ ................................ ............................  46 
7.2.1 Sample Types  ................................ ................................ ................................ ............................  46 
Immune Tolerance Network  CONFIDENTIAL  Page 6 
Protocol ITN058AI: Greenbaum  Version 6.[ADDRESS_219012] (AESIs)  ................................ ................................ .............. 49 
8.2.6 Unexpected Adverse Reaction ................................ ................................ ................................ ... 50 
8.3 COLLECTING AND RECOR DING ADVERSE EVENTS  ................................ .................  50 
8.3.1 Methods of Collection  ................................ ................................ ................................ ...............  50 
8.3.2 Specific Instructions for Recording Adverse Events  ................................ ................................ . 50 
8.3.3 Recording AEs  ................................ ................................ ................................ ..........................  51 
8.3.4 Recording SAEs  ................................ ................................ ................................ ........................  51 
8.4 GRADING AND ATTRIBUTION OF ADVERSE EVENTS  ................................ ..............  51 
8.4.1 Grading of Major Hypoglycemic and Hyperglycemic Events ................................ ...................  51 
8.4.2 Grading for All Other Adverse Events  ................................ ................................ ......................  52 
8.4.3 Attribution  ................................ ................................ ................................ ................................ . 52 
8.5 REPORTING SERIOUS AD VERSE EVENTS  ................................ ................................ .. 53 
8.5.1 Reporting SAEs to the Global Study Sponsor (DAIT, NIAID, NIH) ................................ ........ 53 
8.5.2 Reporting SAEs to Health Authorities  ................................ ................................ ......................  54 
8.5.3 Reporting SAEs to the DSMB  ................................ ................................ ................................ ... 55 
8.5.4 Reporting of Adverse Events to IRBs/ECs  ................................ ................................ ................  55 
8.5.5 Reporting AEs to Genentech, Inc.  ................................ ................................ .............................  55 
8.5.6 Reporting Pregnancy  ................................ ................................ ................................ .................  56 
9. STATISTICAL CONSIDER ATIONS AND ANALYTICA L PLAN ................................ .... 57 
9.1 ANALYSIS SAMPLES  ................................ ................................ ................................ .... 57 
9.2 ANALYSIS OF ENDPOINT S ................................ ................................ ..........................  57 
9.2.1 Primary Endpoint  ................................ ................................ ................................ ......................  57 
9.2.2 Secondary Endpoints  ................................ ................................ ................................ .................  58 
9.2.3 Safety Analysis  ................................ ................................ ................................ ..........................  59 
9.2.4 Medical History  ................................ ................................ ................................ .........................  60 
9.2.5 Use of Medications  ................................ ................................ ................................ ....................  60 
Immune Tolerance Network  CONFIDENTIAL  Page 7 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   9.3 INTERIM ANALYSES AND  DATA REVIEW  ................................ ................................ . 60 
9.4 SAMPLE SIZE  ................................ ................................ ................................ ................  61 
9.5 PHARMACOKINETIC ANAL YSES  ................................ ................................ ................  62 
9.6 REPORTING DEVIATIONS  FROM THE ORIGINAL S TATISTICAL PLAN  ....................  62 
10 STUDY ADMINISTRATION  ................................ ................................ ............................  62 
10.1 SPONSOR  ................................ ................................ ................................ ......................  62 
10.2 RELATIONSHI P WITH INDUSTRY  ................................ ................................ ...............  63 
11 ACCESS TO SOURCE DAT A/DOCUMENTS  ................................ ................................ .. [ADDRESS_219013] OF TABLES  
Table 1. Pediatric Experience with Tocilizumab (N=330)  ................................ ................................ ...... 23 
Table 2. Neutropenia Risk Mitigation  ................................ ................................ ................................ ..... 37 
Table 3. Thrombocytopenia Risk Mitigation  ................................ ................................ ...........................  37 
Table 4. Liver Function Tests Risk Mitigation  ................................ ................................ ........................  38 
Table 5. Elevated Total Bilirubin Risk Mitigation ................................ ................................ ...................  38 
Table 6: Pharmacokinetic Samples  ................................ ................................ ................................ .......... 44 
Table 7. Attribution of Advers e Events ................................ ................................ ................................ ... 53 
Table 8. Summary of Power/Sample Size Results for Pediatric Participants  ................................ .......... [ADDRESS_219014] OF FIGURES  
Figure 1:  C -Peptide Positive Subjects According to T1D Duration and Age at Diagnosis (%)  ............. 15 
Figure 2: Study Design for Tocilizumab in New -Onset T1DM  ................................ ...............................  30 
Immune Tolerance Network  CONFIDENTIAL  Page 8 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   Synopsis  
Title Preserving Beta -Cell Function with Tocilizumab in New -onset Type 1 
Diabetes 
 
Short Title  
 
US IND TCZ in New -onset T1D  
 
117725 
 
Sponsor US and Global Study Sponsor: Division of Allergy, Immunology, and 
Transplantation (DAIT), National Institute of Allergy and Infectious Diseases 
(NIAID), National Institutes of Health (NIH), [LOCATION_003]  
Local Sponsor in Australia: Pharmaceutical Product Developmen t, Inc. ([COMPANY_003]) 
for NIAID, NIH  
 
Conducted by   
[CONTACT_185515] , an NIH grantee  
 
Protocol Co- 
Chairs   
 
 
Accrual Objective   
78 eligible pediatric subjects (6 -17 years old)  and 30-99 eligible adult subjects 
(18-45 years old)  will be enrolled .  Only pediatric participants are eligible for 
randomization after May 15, 2017. 
 
Study Treatment   
Tocilizumab or placebo  
 
Study Design   
This trial will be conducted in the US and Australia as a multi -center, 
prospective, double -blind, placebo -controlled, 2:1 randomized, phase 2 
clinical trial for individuals with recent -onset T1DM aged 6‚àí[ADDRESS_219015] intensive diabetes management.  
The subjects will receive IV infusions of either 8.0 mg/kg (body weight 
‚â•30kg) or 10.0 mg/kg (body weight <30kg) tocilizumab or placebo every 4 
weeks for 24 weeks.  
 
A staggered enrollment plan is being used for this tria l.  Prior to initiating the 
study in the pediatric age group (6 -17 years old), adults (18 -45 years old) were 
randomized 2:[ADDRESS_219016] of 
benefit before opening the trial to pediatric participants.   The result of those 
reviews was to allow enrollment of children and adolescents 6-17 years old.  
 
Study Duration   
Total study duration will be approximately 4 -5 years.   
ÔÇ∑ The enrollment phase is expected to last up to 42 months.   
ÔÇ∑ The study participation phase will be 104 weeks (2 years), which 
includes a treatment phase of 24 weeks and a follow -up phase of 8 0 
weeks. 
 

Immune Tolerance Network  CONFIDENTIAL  Page 9 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   Primary Objective  Determine whether tocilizumab will slow the progression of the autoimmune 
destruction of √ü cells and lead to the preservation of C -peptide secretion in 
T1DM. 
Primary Endpoint  MMTT-stimulated mean 2-hour C-peptide AUC at week 52.   
Secondary 
Endpoints  Efficacy: 
1. MMTT-stimulated mean 2-hour C-peptide AUC at weeks 12, 24, and 
104. 
2. MMTT-stimulated mean 2-hour C-peptide AUC assessed 
longitudinally at weeks 12, 24, 39, 52, 78, and 104. 
3. MMTT-stimulated peak and 4 -hour C-peptide AUC at weeks 52 and 
104 for subjects ‚â•12 years old.  
4. Insulin use (U/kg/day) at weeks 12, 24, 39, 52, 78 and 104; HbA1c 
levels at weeks 12, 24, 39, 52, 78 and 104. 
5. Glycemic control.  
Safety: 
1. Rate of AEs related to infusion reactions and hypersensitivity.  
2. Frequency and severity of all AEs.  
Mechanistic:  
1. Determine the effect of TCZ on the ratio of Treg and Teff .  
 
Exploratory  
Endpoints   
Mechanistic:  
1. Determine effect of T CZ on measures of immune cell number and 
function such as:  
a. Changes in proportions and phenotype of Treg and Teff .  
b. Changes in sensitivity of Teff to suppression by [CONTACT_185516] . 
c. Changes in circulating B cell compartment and activation 
state of innate immune cells including antigen presenting 
cells and NK  cells. 
Metabolic:  
1. Explore the relationship between immune responses, metabolic 
outcomes and clinical variables.  
2. Explore the effect of TCZ on insulin sensitivity.  
 
Inclusion Criteria  1. Male or female aged 6-45 years inclusive who meet the American 
Diabetes Association T1DM  criteria. 
2. Diagnosis of T1DM within 100 days of enrollment  (V0). 
3. Positive for at least one diabetes -related autoantibody, including but 
not limited to:  
a. Glutamate decarboxylase -65 (GAD-65); 
b. Insulin, if obtained within 10 days of the onset of  exogenous 
insulin therapy;  
c. Insulinoma antigen -2 (IA-2); or 
d. Zinc transporter -8 (ZnT8). 
4. Peak stimulated C -peptide level ‚â• 0.2 pmol/mL following a MMTT 
conducted at least 21 days from diagnosis and within 37 days of 
randomization  (V0). 
5. Signed informed consent (and informed assent of minor, if 
applicable).  
 
Immune Tolerance Network  CONFIDENTIAL  Page 10 
Protocol ITN058AI: Greenbaum  Version 6.[ADDRESS_219017] ([COMPANY_003]) or QuantiFERON TB test, history 
of tuberculosis, or active TB infection.  
6. Active infection with EBV as defined by [CONTACT_185517] ‚â• 10,000 
copi[INVESTIGATOR_66487] 106 PBMCs or ‚â• 2,000 copi[INVESTIGATOR_185489] . 
7. Active infection with CMV as defined by [CONTACT_185518] ‚â• 10,[ADDRESS_219018], or both > 1.5 x the upper limit of age-determined normal 
(ULN) or total bilirubin > ULN.  
9. Current or prior treatment that is known to cause a significant, 
ongoing change in the course of T1D or immunologic status.  
10. Current or prior (within last 14 days of screening MMTT visit ) use of 
drugs other than insulin  to treat hyperglycemia (e.g. metformin, 
sulfonylureas, glinides, thiazolidinediones, exenatide, liraglutide, 
DPP-IV inhibitors, or amylin).  
11. Current use of any medication known to significantly influence 
glucose tolerance (e.g., atypi[INVESTIGATOR_16709], di phenylhydantoin, 
niacin). 
12. Any of the following hematologic abnormalities , confirmed by [CONTACT_185519]: 
a. White blood count <3,000/ŒºL or >14,000/ŒºL;  
b. Lymphocyte count <500/ŒºL;  
c. Platelet count <150,000 /ŒºL;  
d. Hemoglobin <8.5 g/dL; or  
e. Neutrophil count <2,000 cells/Œº L. 
13. Females who are pregnant, lactating, or planning on pregnancy 
during the 2 -year study period.  
14. History or diagnoses of other autoimmune disease s, with the 
exception of stable thyroid or celiac disease . 
15. History of alcohol, drug or chemical abuse within 1 year prior to 
screening  (V-1). 
16. Any medical or psychological condition that in the opi[INVESTIGATOR_185490]. 
17. Prior participation in a clinical trial that could increase risks 
associated with thi s clinical trial.  
18. Receipt of live vaccine (e.g. varicella, measles, mumps, rubella, cold -
attenuated intranasal influenza vaccine, bacillus Calmette -Gu√©rin, 
and small pox) in the 6 weeks before randomization  (V0). 
19. High lipid levels (fasting LDL cholesterol ‚â•160 mg/dL  or 
‚â•4.1mmol/L ). 
20. History of  significant allergy (e.g. anaphylaxis) to milk or soy 
proteins. 
Immune Tolerance Network  CONFIDENTIAL  Page 11 
Protocol ITN058AI: Greenbaum  Version 6.[ADDRESS_219019] research organization  
CTCAE Common Terminology Criteria for Adverse Events (version 4.0, May 28, 2009)  
CVD Cardiovascular disease  
DAIT Division of Allergy, Immunology, and Transplanta tion 
DKA Diabetic keto acidosis  
DMARD  Disease-modifying antirheumatic drug  
DSMB Data and Safety Monitoring Board  
EBV Epstein-Barr virus  
EC  Ethics Committee  
FDA US Food and Drug Administration  
FSIVGTT  Frequently -sampled intravenous glucose tolerance test  
Immune Tolerance Network  CONFIDENTIAL  Page 12 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   GAD-65 Glutamate decarboxylase -65 
GCP Good clinical practice  
HBsAg Hepatitis B surface antigen  
HbA1c Glycosylated hemoglobin  
hCG Human chorionic gonadotropin  
HCV Hepatitis C virus  
HDL High-density lipoprotein  
Hgb Hemoglobin  
HIV Human immunodeficiency virus  
IA-2 Insulinoma antigen -2 
IB Investigator‚Äôs Brochure 
ICA Islet cell antibody  
ICH International Conference on Harmonization  
IgA Immunoglobulin A  
IL-[ADDRESS_219020]  
MTX Methotrexate  
NCI-CTCAE National Cancer Institute Common Terminology Criteria for Adverse  Events 
NFŒ∫B Nuclear factor kappa -light-chain-enhancer of activated B cells  
NIAID National Institute of Allergy and Infectious Diseases  
Immune Tolerance Network  CONFIDENTIAL  Page 13 
Protocol ITN058AI: Greenbaum  Version 6.[ADDRESS_219021] Upper limit of normal range  
VZV Varicella zoster  
WHO World Health Organization  
ZnT8 Zinc transporter -8 
Immune Tolerance Network  CONFIDENTIAL  Page 14 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   1. BACKGROUND AND RATIONALE  
1.1 BACKGROUND  AND SCIENTIFIC RATIONALE  
1.1.1 Type 1 diabetes (T1D)  
Type 1 diabetes (T1D) affects about 1 million people in North America, with an 
incidence of approximately 30,000 new cases per year (~15,000 children and ~15,000 
adults‚Äî80 people per day ‚Äîare diagnosed with T1D in the U.S ).[ADDRESS_219022] of ~$9,000 per year, compared to about ~$1,500 for 
those who don‚Äôt have diabetes.[ADDRESS_219023] of care for 
those with T1D for several decades, insulin therap y is woefully inadequate to treat this 
disease.  Thus, while the overall rate of complications is decreasing,3 T1D remains a 
substantial burden to those living with the disease and their families, and T1D  still 
results in decreased quality of life (QOL), and increased morbidity and mortality.  The 
pi[INVESTIGATOR_510] T1D in the US has been recently described in a series of studies conducted 
by [CONTACT_941] T1D Exchange which includes data on more than 25,[ADDRESS_219024] majority of youth with T1D do 
not meet the American Diabetes Association ( ADA) HbA1c targets.  This is 
particularly true among adolescents, where only 21% of T1D adolescents (ages 13 -20) 
had HbA1c l evels <7.5%, as recommended.  Less than half of those 6 -12 years of age 
met the target HbA1c level of <8%, and only 64% of those younger than age 6 met the 
target of 8.5%, which corresponds to significant hyperglycemia.4  The T1D Exchange 
also documented that 7% of those with T1D experienced severe hypoglycemia 
(resulting in seizure or coma) and 8% had di abetic ketoacidosis (DKA) during the 
previous 12 months.5  Strikingly, 18.6% of those with T1D >[ADDRESS_219025] severe 
hypoglycemia.6  The intractable problem of hypoglycemia is also highlighted by [CONTACT_185520] -management is associated with reduced DKA as 
compared to those with poorer control, but the rate of severe hypoglycemia was 
independent of these behavior s.7  The T1D Exchange data also found that ~5 -10% of 
more than 6,000 individuals with T1D were classified as having probable major 
depression; this was associated with more complicati ons, higher HbA1c, more DKA, 
and more severe hypoglycemia.[ADDRESS_219026] understanding the genetic, environmental, and immunologic 
basis for T1D, the prevention and cure of this condition remains elusive.  While the 
,PPXQH7ROHUDQFH1HWZRUN &21),'(17,$/ 3DJH
3URWRFRO,71$,*UHHQEDXP  9HUVLRQ -XQH
7&=LQ1HZRQVHW7' DXWRLPPXQHSDWKRJHQHVLVRI7'LV ZHOOHVWDEOLVKHGDQGFOLQLFD OWULDOVZLWK
LPPXQRWKHUDSHXWLFDJHQWVWDUJHWLQJ7FHOOV%FHOOVDQGFRVWLPXODWLRQKDYH
GHPRQVWUDWHGSUHVHUYDWLRQRILQVXOLQVHFUHWLRQWKHVHHIIHFWVK DYHQRWEHHQORQJ
ODVWLQJ1HYHUWKHOHVVSUHVHUYDWL RQRIHYHQPRGHVWDPRXQWVRIHQGRJHQR XVLQVXOLQ
VHFUHWLRQVLJQLILFDQWO\LPSUR YHVTXDOLW\RIOLIHDQGUHGXFHVOR QJWHUPFRPSOLFDWLRQV
WKXVWKHUDSLHVWKDWFDQVDIHO\DOWHUWKHFRXUVHRIEHWDFHOOGH VWUXFWLRQZRXOGKDYH
VLJQLILFDQWFOLQLFDOLPSDFW
7'LVDSDUWLFXODUEXUGHQLQFKLOGUHQ7KHZRUOGZLGHLQFLGHQFHRI7'LV
LQFUHDVLQJUDSLGO\LQFKLOGUHQZLWKWKHJUHDWHVWSHUFHQWDJHLQF UHDVHLQWKRVHXQGHUDJH
:KLOH7'FDQRFFXULQDOODJHVWKHQDWXUDOKLVWRU\DQGEX UGHQRIGLVHDVHLV
GLIIHUHQWLQWKRVHGLDJQRVHGDV FKLOGUHQDVFRPSDUHGWRDGXOWV 'LVHDVHSURJUHVVLRQLV
GLVWLQFWO\VORZHULQ DGXOWVZLWKDUDWHRIGHFOLQHRIEHWDFHOO IXQFWLRQWKDWLVaIROG
VORZHUWKDQWKDWLQWKHSHGLDWU LFSRSXODWLRQ$VLOOXVWUDWHGE HORZ
)LJXUHWKLVUHVXOWVLQPDUNHGGLII HUHQFHVRYHUWLPHVXFKWKDWFRQVL GHUDEO\PRUH
LQGLYLGXDOVGLDJQRVHGDVDGXOWVD VFRPSDUHGZLWKFKLOGUHQUHWDL QVLJQLILFDQWOHYHOVRI
&SHSWLGHGHFDGHVDIWHUGLDJQRVLV
)LJXUH&3HSWLGH3RVLWLYH6 XEMHFWV$FFRUGLQJWR7''XUDWLR QDQG$JHDW
'LDJQRVLV

6HYHUDOIDFWRUVKDYHEHHQVWXGLHGDVSUHGLFWRUVRIWKHQDWXUDO KLVWRU\RI»ïFHOOUHVSRQVH
DQGGHFOLQH7KHPRVWLPSRUWDQWRIWKHVHIDFWRUVLVDJH.DUMDODLQHQHWDOUHSRUWHG
WKDW7'0WKDWEHJLQVLQDGXOWKRRG¬±\HDUVLVFKDUDFWHU L]HGE\DORQJHU
DV\PSWRPDWLFSHULRGEHIRUHGLDJ QRVLVDQGEHWWHUSUHVHUYDWLRQRI UHVLGXDO»ïFHOO
IXQFWLRQWKDQWKHW\SHRI7'0REVHUYHGEHJLQQLQJLQFKLOGKRRG ¬±\HDUV
,QIDFWWKLVREVHUYDWLRQKDV EHHQFRQILUPHGE\RWKHUVLQFOXGLQ J%RQIDQWLHWDOZKR
IRXQGVLJQLILFDQWO\UHGXFHG& SHSWLGHOHYHOVLQFKLOGUHQZLWK7 '0GLDJQRVHGDWOHVV
WKDQ\HDUVRIDJHFRPSDUHGWRWKRVHZLWKGLDJQRVLVDWDQROGH UDJH
7KHEXUGHQRIGLVHDVHLVDOVRGLIIHUHQWLQFKLOGUHQDVFRPSDUHG ZLWKDGXOWV7KHUHDUH
VLJQLILFDQWSV\FKRORJLFDODQGILQDQFLDOLPSDFWVZLWKLQIDPLOLHV GHDOLQJZLWKDOLIH
WKUHDWHQLQJFKURQLFGLVHDVHLQDFKLOG0RUHRYHUZKLOHJO\FHP LFYDULDWLRQLVD
FRPSRQHQWRI7'LQDOOLQGLYLGXDOVUHFHQWGDWDVXJJHVWVDSDU WLFXODULPSDFWLQD

Immune Tolerance Network  CONFIDENTIAL  Page 16 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   developi[INVESTIGATOR_185491] n with neuroanatomical alterations and diminished cognitive ability .20  
Therefore, safe and effective interventions that can modify the course of T1D in 
pediatric populations are urgently needed.   
1.1.2 Tocilizumab  
IL-6 is a systemic  cytokine, participating in proinflammatory pathways associated 
with immunity and autoimmunity.  In addition, IL -6 plays an important role in the 
communication between the innate and adaptive immune systems, mediated through 
the development and function of  regulatory T (Treg) and pathogenic T effector (Teff) 
cells such as Th17 cells .  Data from murine models suggest that IL -6 receptor ( IL-6R) 
blockade may promote both anti -inflammatory and pro -regulatory mechanisms 
simultaneously.   Therefore, IL -6 is considered a  ‚Äúmaster switch‚Äù that regulates Teff 
vs. Treg responses, and blockade of IL -6 signaling can restore  immune tolerance in 
the setting of autoimmunity.  This mechanism is likely responsible for the clinical 
efficacy of IL-6 receptor blockade in autoimmunity as tocilizumab therapy decreases 
the frequency of Th17 cells and increases the frequency of Treg cells in patients with 
rheumatoid arthritis (RA ).[ADDRESS_219027] that Treg  function is incapacitated by 
[CONTACT_185521], which is full of proinflammatory cytokines, particularly 
IL-6, which drives Teff lineages and/or inhibits FOXP3  a Treg transcriptional 
regulator.  CD4 T cells co -treated with TGFŒ≤ and IL -[ADDRESS_219028].  In 
multiple mouse models, including autoimmune diabetes, a pi[INVESTIGATOR_185492] -6 in 
disease progression, operating through Treg inhi bition, has now been v alidated.22  In 
an in vivo study with the non-obese diabetes ( NOD) type [ADDRESS_219029] shown that T eff from T1D subjects are resistant 
to suppression by T reg from healthy controls .24  This resistance of Teff cells to 
suppression by [CONTACT_185522] -6.  Importantly, in humans, the IL6R 
358Ala allele, which impairs IL -6 signaling, confers a reduced risk of T1D.  The 
358Ala allele inhibits IL -6 signaling by [CONTACT_185523] -
bound IL-6 receptor, thereby [CONTACT_1541] a compelling rationale for evaluating an anti -
IL-6 receptor antibody, such as tocilizumab, in the treatment of new -onset T1D.25  
Other work has demonstrated an increase  in Th17 cells in T1D subjects , including 
islet-antigen specific Th17 cells.26,27  Mechanistically IL -17 enhances IL-1ÔÅ¢, IFN-
ÔÅßÔÄ¨ÔÄ†andÔÄ†ÔÅîÔÅéF-ÔÅ°-induced apoptosis in human islets .[ADDRESS_219030] IL -17 producing cells may be pathogenic in the early stages of T1D onset .28  
As noted above, tocilizumab treatment reduced the number of Th17 cells in 
rheumatoid arthritis subjects.21  Thus, immune dysregulation is a key component of 
T1D and restoration of Teff sensitivity to suppression by [CONTACT_185524] 17 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   activity and/or inhibition of Teff is likely to alter the course of disease.  IL-6R 
blockade with tocilizumab has the potential for achieving that goal.  
The IV formulation of TCZ is approved in the EU, US, and Japan for RA, sJIA, and 
pJIA. IV TCZ is also approved in more than 75 other countries for the treatment of 
RA, in more  than 50 additional countr ies for the treatment of sJIA, and over 30 other 
countries for the  treatment of pJIA. In India and Japan, IV TCZ has additional 
indications for treatment in  Castleman‚Äôs disease. The SC formulation of TCZ is 
approved in more than 30 countries  (including  EU, US, New Zealand, Switzerland, 
Canada, Japan, South Korea and Taiwan) for  the treatment of RA.  
Tocilizumab (TCZ) is an anti-IL-6 receptor antibody that is approved in the US and 
Australia for the treatment of adult rheumatoid arthritis, systemic juvenile i diopathic 
arthritis (sJIA) in patients 2 years of age and older , and polyarticular juvenile 
idiopathic arthritis (pJIA) in patients 2 years of age and older .  In the US, tocilizumab 
is additionally approved for giant cell arteritis, and in Japan, tocilizum ab is also 
approved for Castleman‚Äôs disease .  In addition , preliminary efficacy has been shown 
in a variety of other autoimmune diseases.  In light of the murine data described above 
and a strong theoretical rationale, a trial of tocilizumab  in new-onset T1D is 
particularly attractive because there is substantial experience in pediatric populations 
with approval for both sJIA and pJIA.  It is well known that T1D is a particular 
burden in children in whom the disease is more aggressive with a more rapid loss of 
residual Œ≤ -cell function.[ADDRESS_219031] whether ACTEMRA¬Æ (tocilizumab ) can preserve remaining beta 
cells in individuals with recently diagnosed type [ADDRESS_219032] intensive diabetes treatment w ith insulin and dietary 
management.  Subjects will be randomly assigned (2:1 drug -placebo) to receive either 
monthly IV infusions of tocilizumab or placebo for 6 months (total of 7 infusions).   
The effects of the treatment on general and diabetes -specific immune responses and 
the deterioration of Œ≤ -cell function that occurs in T1D will be studied to determine the 
study drug‚Äôs mechanism of action.  Furthermore, how the drug alters T1D -associated 
immune responses and whether the drug has prolonged clinical efficacy will also be 
studied. 
As of the date of this current protocol version,  review of data from the adult cohort  
has been completed by [CONTACT_185525] .  Enrollment of pediatric participants age 6 -
17 years old, inclusive, is ongoing.  
Immune Tolerance Network  CONFIDENTIAL  Page 18 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   1.2 PRECLINICAL AND CLINICAL EXPERIENCE  
1.2.1   Preclinical Studies  
[IP_ADDRESS] Preclinical Safety Data  
[IP_ADDRESS].1  Overview  
 
 
 
 
 
 
[IP_ADDRESS].2  Toxicity Studies  
 
 
 
 
[IP_ADDRESS] Preclinical Efficacy Data  in Other Autoimmune Disease 
 
   
 
  
  
 
   
1.2.2 Clinical Studies   
[IP_ADDRESS] Efficacy and Safety Data  for Tocilizumab  
[IP_ADDRESS].1  Overview  
Tocilizumab  
 
    
 
 
  
  
 
 
 

Immune Tolerance Network  CONFIDENTIAL  Page 19 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   Efficacy 
 
 
 
 
  
 
 
   
  
 
 
 
 
   
  
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
   

Immune Tolerance Network  CONFIDENTIAL  Page 20 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D    
 (GI) 
perforations) increased with increasing duration of treatment.    
[IP_ADDRESS].2  Giant Cell Arteritis  
  
 
 
 
 
 
 
 
 
 
 
 
 
[IP_ADDRESS].3  System ic Juvenile Idiopathic Arthritis  
 
 
 
 
 
 
   
  
 
 
 
 
 
 
 
 
 
 
 
Safety 

Immune Tolerance Network  CONFIDENTIAL  Page 21 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D    
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
[IP_ADDRESS].4  Polyarticular Juvenile Idiopathic Arthritis  
 
 
Efficacy 
 
 
 
 
 
 
 
 
 
   
Safety 
 
 
 
  

Immune Tolerance Network  CONFIDENTIAL  Page 22 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D    
 
 
 
 
 
 
 
[IP_ADDRESS].5  Castleman‚Äôs Disease  
 
 
 
 
 
 
 
 
  
[IP_ADDRESS].6  Other Autoimmune and Inflammatory Diseases  
 
 
 
 
  
[IP_ADDRESS].[ADDRESS_219033] measurements of insulin action or 
secretion were performed.  Also of no te are the results of a recent M endelian 
randomization analysis for a SNP in the IL6R gene (Asp358Ala ) that phenotypi[INVESTIGATOR_185493], which showed reduced risks for coronary 
heart disease and type [ADDRESS_219034] a causal role in atherosclerosis and, possibly, insulin resistance.  

Immune Tolerance Network  CONFIDENTIAL  Page 23 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   [IP_ADDRESS].8  Pediatric Experience with Tocilizumab  
As noted previously, tocilizumab is approved for use in children 2 years of a ge and 
older with sJIA and pJIA .  Tocilizumab has been studied in two phase 3 clinical trials 
(WA18221 and WA19977) and a supportive phase 3 study (MRA316JP) performed in 
Japan with pediatric populations.41,45-51  The clinical trials included a to tal of 367 
pediatric subjects, 330 of whom received tocilizumab [ 142 subjects with sJIA and 188 
subjects with pJIA ].  See Table [ADDRESS_219035] age breakdown data below.  
Table 1. Pediatric Experience with Tocil izumab (N= 330) 
 
Indication  
 sJIA 
Systemic Juvenile 
Idiopathic Arthritis  sJIA 
Systemic Juvenile 
Idiopathic 
Arthritis  pJIA 
Polyarticular 
Juvenile Idiopathic 
Arthritis  
Trial WA18221 (TENDER)  
[Ongoing]  MRA316JP  
[Completed]  WA19977 
(CHERISH)  
[Ongoing]  
Phase III (Pi[INVESTIGATOR_22735])  III (Supportive)  III (Pi[INVESTIGATOR_22735])  
Sponsor [COMPANY_002]/GEN  Chugai [COMPANY_002]/GEN  
ClinicalTrials.Gov 
Identifier [STUDY_ID_REMOVED]  
 [STUDY_ID_REMOVED] (open -
label lead -in, double -
blind phases)  
[STUDY_ID_REMOVED] (open -
label extension phase)  [STUDY_ID_REMOVED]  
Number of 
Subjects Who 
Received TCZ 75 67 total = 56 [Phase 
III]  + 11 [Phase II];  
Median exposure to 
TCZ = 3.4 yrs (177 
weeks); Part 1=188 total 
(open-label) every 4 
wks X4 = 16 wks;  
Part 2=82 [DB, rand. 
1:1 TCZ (n=82) or 
placebo (n=81)] for 24 
wks (starting at wk 
16); 
Age Range that 
Received TCZ 10 ¬± 4.6 yrs  
 2 to 19 yrs  2 to 17 yrs  
TCZ Dose TCZ treated subjects with 
body wt < 30 kg received 
12 mg/kg those with body 
wt ‚â• 30 kg received 8 
mg/kg.  TCZ was 
administered, every 2 
weeks. TCZ treated subjects 
received 8 mg/kg 
every 2 weeks.  TCZ treated subjects 
with body wt < 30 kg 
were randomized (1:1) 
to receive either 8 
mg/kg or 10 mg/kg of 
TCZ and pts with 
body wt ‚â• 30 kg 
received 8 mg/kg of 
TCZ, every 4 weeks.  
1.3 SUMMARY OF KNOWN A ND POTENTIAL RISKS A ND BENEFITS 
FOR HUMAN  PARTICIPANTS   
1.3.1   Overview  
Like any immunomodulating therapy, the primary risks of tocilizumab relate to 
infections; however, these are generally well tolerated and the use of this drug is 
increasing rapi[INVESTIGATOR_185494] (rheumatoid  arthritis, 
systemic juvenile idiopathic arthritis, and polyarticular juvenile idiopathic arthritis) .  
Immune Tolerance Network  CONFIDENTIAL  Page 24 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   The information provided here is summarized from the current F. Hoffman La -[COMPANY_002] 
LTD Investigator‚Äôs Brochure for tocilizumab  and country-specific Package Insert and 
is compi[INVESTIGATOR_185495] 2 years of age and older 
with systemic juvenile idiopathic arthritis , polyarticular juvenile idiopathic arthritis,  
and rheumatoid arthritis.  
1.3.2   Risks  
[IP_ADDRESS]  Opportunistic Infections and Seri ous Infections  
Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive 
fungal, viral, protozoal, or other opportunistic pathogens have been reported in 
patients receiving immunosuppressive agents including tocilizumab for rheumato id 
arthritis.  
[IP_ADDRESS] Gastrointestinal Perforations   
A total of 30 cases of medically confirmed serious GI perforation ( primarily as 
complications of diverticulitis in RA patients, but also including those related to 
malignancy) were reported in clinical trials,  corresponding to a rate of 0.2 per 100 
patient-years.  No GI perforations were seen in the two phase 3 studies in juvenile 
idiopathic arthritis with a pediatric population.  
[IP_ADDRESS] Laboratory Abnorma lities  
Neutrophils  
Treatment with tocilizumab in RA was associated with a highe r incidence of 
neutropenia.   An observed decrease in neutrophils occurs in about half the subjects in 
trials, occurred largely within the normal range, and was reversible upon 
interruption/discontinuation of TCZ.  Out of more than 40 00 patients, 5% had 
neutrophil counts < 1000‚àí500/mm3 and 33 (< 1%) had counts < 500/mm3.  There was 
no clear relationship between decreases in neutrophils below 1000/mm3 and the 
occurrence of serious infections.  
Platelets  
Treatment with tocilizumab  in RA was associated with a reduction in platelet counts. 
Transient decreases in platelet counts below 100,000/mm3  occurred in 1.3% and 1.7% 
of patients on 4 mg/kg and 8 mg/kg TCZ + DMARD, respectively, compared with 
0.5% of patients in the placebo + DMARD grou p.  In the long-term exposure  all-
exposure population, 52/4002 patients (1.3%) had < 75,000‚àí50,000/mm3; 18 patients 
(0.4%) had < 50,000‚àí25,000/mm3; and 14 patients (0.3%) had platelet counts < 
25,000/mm3. There was no clear relationship between thrombocytopenia and clinical 
symptoms.  
Liver Function Tests  
Immune Tolerance Network  CONFIDENTIAL  Page 25 
Protocol ITN058AI: Greenbaum  Version 6.[ADDRESS_219036] were 
transient and returned towards normal with treatment interruption or treatment 
discontinuation.  Transient elevations in ALT above three times the upper limit of 
normal (ULN) were observed in 6.5% of patients receiving 8 mg/kg TCZ + DMARD 
groups, respectiv ely, compared with 1.5% of patients in the placebo + DMARD 
group. There is no evidence to date of a correlation between liver enzyme changes 
with TCZ and serious hepatic events; the majority of elevated transaminase reports 
have shown no clinical sequelae.   A total of 99 patients (2.4%) in the long term 
exposure population were prematurely withdrawn due to transaminase elevations.  The 
percentage of patients with an increase in indirect bilirubin > ULN was higher in 
patients receiving TCZ than patients in th e control group.  Based on the long term 
TCZ exposure data, 0.6% of patients had an indirect bilirubin level > 2 √ó ULN.  
However, the change in bilirubin levels when receiving TCZ treatment did not result 
in negative clinical outcomes.  
Lipi[INVESTIGATOR_185496], triglycerides, LDL cholesterol, and/or HDL cholesterol.  
LDL levels  increased in  the 8 mg/kg treatment groups and responded appropriately to 
statin therapy.  Long -term data from the TCZ phase 3 program over a mean duration 
of 3.7 years show no evidence that the observed changes in lipid levels in the TCZ -
treated patients result in an increase in the rate of reported cardiovascular events. 
Rates of myocardial infarction and stroke were similar across the TCZ and control 
treatment groups.   
A similar pattern of liver enzyme elevation, low neutrophil count, low platelet count 
and lipid el evations is noted with tocilizumab treatment in the sJIA population.  
[IP_ADDRESS] Immunosuppression  
The impact of treatment with tocilizumab on the development of malignancies is not 
known.  Tocilizumab is an immunosuppressant, and treatment with this class of drugs 
may result in an increased risk of malignancies.   In the 6-month double -blind studies  
in RA, the rate of malignant neoplasms was 1.33 and 1.27 events per 100 patient -years 
in the TCZ and control groups, respectively.  
[IP_ADDRESS] Hypersensitivity Reactions, Including A naphylaxis  
Hypersensitivity reactions, including anaphylaxis and death, have been reported in 
association with infusion of tocilizumab.  Anaphylaxis and other hypersensitivity 
reactions that required treatment discontinuation were reported in 0.1% (3 out o f 
2644) of RA patients in the 6 -month controlled trials, and in 0.2% (8 out of 4009) of 
patients in the all -exposure rheumatoid arthritis population .  Anaphylaxis and other 
hypersensitivity reactions that required treatment discontinuation were reported in  
Immune Tolerance Network  CONFIDENTIAL  Page 26 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   0.9% (1 out of 112 patients) of patients  in the sJIA controlled trial.  No reports of 
anaphylaxis or serious hypersensitivity reactions were reported in the pJIA controlled  
trial (N=188).  In the postmarketing  setting, a patient with a previous infusion reaction 
and premedicated with steroids and antihistamines experienced fatal anaphylaxis 
during subsequent treatment with tocilizumab.  
[IP_ADDRESS] Other Potential Risks  
Demyelinating Disorders  
The impact of treatment with tocilizumab  on demyelinating disorders is not known, 
but multiple sclerosis and chronic inflammatory demyelinating polyneuropathy were 
reported rarely in RA clinical studies.  
Vaccinations  
Live vaccines should not be given concurrently with tocilizumab as c linical safety has 
not been established.   No data are available on the secondary transmission of infection 
from persons receiving live vaccines to patients receiving tocilizumab.  Limited data 
are available on the  safety and  effectiveness of vaccination in  patients receiving 
tocilizumab , but to date no impairment in seroprotection has been noted .  
Viral Reactivation  
Though rarely reported within the TCZ program due to exclusion criteria at study 
entry, reactivation of viral and other serious infections (e.g. EBV , herpes zoster  and 
TB) have been observed with  biologic therapi[INVESTIGATOR_185497], including TCZ.  
 Anti-TCZ Antibodies  
In the phase 3 RA trials,  serum samples of 44/3945 patients (1.1%) tested positive 
post baseline  in the confirmation assay for anti -TCZ antibodies. Five of the 44 anti -
TCZ antibody positive patients experience an anaphylactic reaction.  The remaining 
39 patients did not.  
Of 112 pediatric patients treated with tocilizumab in the sJIA trials, 2 (1.8%) 
developed positive anti -tocilizumab  antibodies, of whom one experienced SAEs 
(urticaria and angioedema) consistent with an anaphylactic  reaction which led to 
withdrawal . Of 19 pediatric patients treated with tocilizumab in the Japanese pJIA 
trial, one was positive for anti -TCZ antibodies.  
Drug Interaction  
The formation of CYP450 enzymes may be suppressed by [CONTACT_185526] (e.g. IL -6) during chronic inflammation. Therefore, it is expected that for 
molecules that antagonize cytokine activity, such as TCZ, the formation of CYP450 
enzymes could b e normalized. The clinical implications of this are unknown.  
Immune Tolerance Network  CONFIDENTIAL  Page 27 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   1.3.3   Potential Risks and Benefits of Trial Participation for Children  
As noted in section [IP_ADDRESS]. 8, tocilizumab has been used in pediatric populations and  
is approved for treatment of both sJIA and pJIA for children age  2 and older in many 
countries.  For children receiving placebo, t he study procedures  including blood 
draws, mixed meal tolerance testing , and IV placebo administration are either minimal 
risk or slightly greater than  minimal risk ; these subjects have the possibility of benefit 
in the close monitoring  of their newly diagnosed T1D .  For those receiving 
tocilizumab, the study procedures are greater than minimal risk; however, overall 
tocilizumab has been well tolerated in both pediatr ic and adult populations .  The 
rationale for a  prospect of benefit in children is motivated by [CONTACT_185527].  There are currently no approved interventions for new -onset T1DM.   
It is important to recognize that the natural history of disease in T1DM is considerably 
different in children as compared with adults, with a dults having a much more 
indolent disease course.  The average reduction in MMTT -stimulated C -peptide AUC 
mean in adults is ~ 7.5% at 6 months and ~ 15% at 12 months, which is half of the 
change seen in children.  While the mechanisms underlying this diffe rence is 
unknown, these difference in disease course are likely to be reflected in responses to 
therapy as well.  Like RA and sJIA or pJIA, T1D is a different disease in different 
aged populations.  Thus, either efficacy or lack of efficacy in an adult population is 
not likely to be informative as to efficacy or lack thereof in a pediatric population.   
Nonetheless, this study will be initiated in adults to assure no unexpected harms and 
both safety a nd efficacy data will be reviewed by [CONTACT_185528].  
Assent of children along with consent of the parents will be obtained prior to any 
study procedures.  This research proposal in children is therefore consistent with 
[LOCATION_002] Department of Health and Human Services, Protection of Human 
Subjects, subpart D, section 46.405 (research involving greater than minimal risk but 
presenting the prospect of direct benefit to individual subjects) and with FDA 21 CFR 
50.52 [Subpar t  D].  (Clinical investigations involving greater than minimal risk but 
presenting the prospect of direct benefit to individual subjects).  
1.3.[ADDRESS_219037] ADA guidelines.45  
Although intensive diabetes management is recommended for all patients with T1DM, 
it is not always available to all subjects in the community.  The Diabetes Control and 
Complications Trial (DCCT) research group documented that improved metabolic 
control slows the onset of some long -term complications.[ADDRESS_219038] of care, with 
Immune Tolerance Network  CONFIDENTIAL  Page 28 
Protocol ITN058AI: Greenbaum  Version 6.[ADDRESS_219039] on lowering the risk for long -term complications for many years to follow; i.e., 
there appears to be a ‚Äúmetabolic memory‚Äù th at influences later risk.  This effect has 
been documented in the Epi[INVESTIGATOR_146714] 
(EDIC) study, the long -term follow -up of the DCCT cohort.13,14,53-55  Although the 
conventional group (with less stringent metabolic control) and the intensive group 
(with near -normal metabolic control) have had comparable HbA 1c levels since the end 
of the formal DCCT study, the intensive group continues to have significantly lower 
risk for complications [ADDRESS_219040], where those subjects with residual C -peptide had impro ved 
metabolic control, with lower risk for severe hypoglycemia and less likelihood of 
microvascular complications.   
2. OBJECTIVES  
2.1 PRIMARY OBJECTIVE  
Determine whether t ocilizumab will slow the progression of the autoimmune 
destruction of √ü cells and lead to th e preservation of C -peptide secretion in T1DM.  
2.2 SECONDARY OBJECTIVES  
1. Longitudinal analysis of HbA1c, insulin dose (units/kg) and blood glucose by 
[CONTACT_1570].  
2. Determine the efficacy and safety of tocilizumab in participants with T1DM.  
3. Determine how the ratio of Treg/Teff is altered with tocilizumab treatment    
2.3 EXPLORATORY OBJECTIV ES 
Mechanistic studies:  
1. Investigate  the mechanism of action for tocilizumab in the maintenance of √ü -cell 
function and determine whether the loss of tolerance associated with this disease 
is reversed.  
 
 
 
Immune Tolerance Network  CONFIDENTIAL  Page 29 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   Metabolic:  
1. Determine whether treatment with tocilizumab  improves blood glucose and 
HbA1c and reduces individual insulin requirements.  
2. Explore whether tocilizumab affects insulin sensitivity.  
3. STUDY DESIGN 
3.1 DESCRIPTION  
This trial will be conducted in the US and Australia as a multi -center, prospective, 
double-blind, placebo -controlled, 2:1 randomized, phase 2 clinical trial for individuals 
with recent -onset T1DM aged 6‚àí45 years  old.  78 eligible pediatric subjects  (6-17 
years old)  and at least 30 eligible adult subjects  (18-45 years old) will be enrolled (see 
Figure 2).  All groups  will receive standard intensive diabetes manage ment.  The 
subjects will receive IV infusions of either 8.0 mg/kg (body weight ‚â•30kg) or 10.0 
mg/kg (body weight  <30kg) tocilizumab or placebo every 4 weeks for 24 weeks.   
 
A staggered enrollment plan is being used for this trial.  Prior to initiating the study in 
the pediatric age group (6 -17 years old),  adults (18 -45 years old) were randomized 2:[ADDRESS_219041] of benefit  and allowed  opening the trial 
to pediatric participants  (children and adolescents 6-17 years old ).   
 
The protocol continue d to enroll adult participants during and after evaluation of the 
initial cohort with 55 eligible adult partic ipants enrolled in this clinical trial .  Only 
pediatric participants  are eligible for randomization after May 15, 2017 . 
,PPXQH7ROHUDQFH1HWZRUN &21),'(17,$/ 3DJH
3URWRFRO,71$,*UHHQEDXP  9HUVLRQ -XQH
7&=LQ1HZRQVHW7' C-Peptide / 
Safety Review of 
Week 12 data*‚â•10
Follow-up at 
weeks 39 & 52
Follow-up at 
weeks 78 & [ADDRESS_219042] 30 adult 
participants age 18-45 
(Randomly assign 2:1)
‚â•20
Tocilizumab 8 mg/kg (weight ‚â• 30kg) 
IV every 4 weeks for 24 weeks
Placebo IV every 4 weeks for 24 weeks26
Follow-up at 
weeks 39 & 52Follow-up at 
weeks 39 & 52
Follow-up at 
weeks 78 & 104Follow-up at 
weeks 78 & 104
Enroll 78 pediatric 
participants age 6-17 
(Randomly assign 2:1)
52
Tocilizumab 8 mg/kg (weight ‚â• 30kg) 
or 10 mg/kg (weight < 30 kg) 
IV every 4 weeks for 24 weeks
Placebo IV every 4 weeks for 24 weeks
Follow-up at 
weeks 39 & 52
Follow-up at 
weeks 78 & 104
Assess Primary Endpoint at week 52:  C-peptide AUC in response to 2-hr MMTT
Assess Secondary Endpoints at week 104

)LJXUH6WXG\'HVLJQIRU7 RFLOL]XPDELQ1HZ2QVHW7'0

1RWH7KLVILJXUH VKRZVWKHRULJLQDOVWXG\GHVLJQ7KHUHZHU HDGXOWSDUWLFLSDQWVUDQGRPL]HG
EHIRUHRSHQLQJWKHVWXG\WRSH GLDWULFSDUWLFLSDQWV\HDUV ROG
 678'<'85$7,21
 7RWDOVWXG\GXUDWLRQZLOOEHDSSUR[LPDWHO\\HDUV
x7KHHQUROOPHQWSKDVHLVH[SHFWHGWRODVWXSWRPRQWKV
x7KHVWXG\SDUWLFLSDWLRQSKDVHZLOOEHZHHNV\HDUVZKLF KLQFOXGHVD
WUHDWPHQWSKDVHRIZHHNVDQGDIROORZXSSKDVHRIZHHNV
Immune Tolerance Network  CONFIDENTIAL  Page 31 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   3.3 STUDY ENDPOINTS  
3.3.1 Primary Endpoint  
The primary endpoint is a MMTT -stimulated mean 2-hour C-peptide AUC at week 
52.  The mean 2 -hour C-peptide AUC, measured in pmol/ml, is computed by [CONTACT_185529] g 
the total AUC by 120 minutes. 
3.3.2 Secondary Endpoints  
Efficacy:  
1. MMTT-stimulated mean 2-hour C-peptide AUC at weeks 12, 24, and 104 . 
2. MMTT-stimulated mean 2-hour C-peptide AUC assessed longitudinally at weeks 
12, 24, 39, 52, 78, and 104. 
3. MMTT-stimulated peak and 4 -hour C-peptide AUC at weeks 52 and 104 for 
subjects ‚â•12 years old.  
4. Insulin use (U/kg/day) at weeks 12, 24, 39, 52, 78 and 104; HbA 1c levels at weeks 
12, 24, 39, 52, 78 and 104. 
5. Glycemic control .  
Safety: 
1. Rate of AEs related to infusion reactions and hypersensitivity.  
2. Frequency and severity of all AEs.   
Mechanistic  
1. Determine the effect of TCZ on the ratio of Treg and Teff. 
3.3.3 Exploratory Endpoints   
Mechanistic:  
1. Determine effect of T CZ on measures of immune cell number and function such 
as: 
a. Changes in proportions and phenotype of Treg and Teff .  
b. Changes in sensitivity of Teff to suppression by [CONTACT_185516] . 
c. Changes in circulating B cell compartment and activation state of innate 
immune cells including antigen presenting cells and NK cells.  
Metabolic:  
1. Explore the relationship between immune responses, metabolic outcomes and 
clinical variables.  
2. Explore the effect of TCZ on insulin sensitivity.  
3.[ADDRESS_219043] ION OF DRUG, ROUTE, DOSE, AND 
REGIMEN  
The dose of 8 mg/kg every 4 weeks via the IV route is the FDA  and Australian, 
Therapeutic Goods Administration  (TGA)-approved dose for adults in rheumatoid 
Immune Tolerance Network  CONFIDENTIAL  Page 32 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   arthritis and will be used for adults and children ‚â• 30kg in this study .  For children 
<30 kg, TCZ will be dosed at 10 mg/kg.   For systemic juvenile idiopathic arthritis  
(sJIA), the FDA -approved dose is 8 mg/kg every 2 weeks for patients with body 
weight ‚â• 30kg and 12 mg/kg every 2 weeks for patients with body weight < 30 kg.   
However,  in recent clinical trials of polyarticular juvenile idiopa thic arthritis  (pJIA), 
other dosing regimens were tested  in patients age 2 -17.  Participants with body mass < 
30 kg received 8 mg/kg or 10 mg/kg every 4 weeks.  Both pharmacokinetic 
measurements and clinical outcome in the 8 mg/kg ‚â• 30 kg group were more s imilar 
to the 10 mg/kg < 30 kg group than the 8 mg/kg <[ADDRESS_219044] the systemic inflammation seen 
in sJIA.  The dosing frequency may be altered if an adverse event is encountered as 
outlined in section  5.2. 
In order to preserve blinding of the study, participants recei ving placebo will be given 
an IV infusion of equal volume and appearance to treatment on the same schedule, 
formulated and prepared by [CONTACT_129583].  Placebo will be saline.  
3.5 PREMATURE TERMINATIO N OR SUSPENSION OF T HE TRIAL  
3.5.1 Ongoing Review  
As described in Section 10.1 of the protocol, this clinical trial is conducted through 
the NIAID  NIH-funded Cooperative Agreement awarded to the Benaroya  Research 
Institute at Virginia Mason (Seattle, WA) (BRI) to support the Immune Tolerance 
Network (ITN), a collaborative network for clinical research.  The ITN provide s 
financial support for the conduct of the clinical trial to the clinical sites through 
subcontracts between the BRI and the clinical sites.  The NIAID  NIH serves as the US 
Sponsor of the Investigational New Drug application (IND) for the Protocol and the 
Global Sponsor in Australia (represented by [CONTACT_185530], 
Inc. ([COMPANY_003]) as Local Sponsor in Australia) and  is responsible for all regulatory filings 
and safety reporting.  In addition, DAIT, NIAID  NIH has appointed a medical monitor 
and convenes a Data and Safety Monitoring Board (DSMB)  as described below .   
The joint Natio nal Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 
and NIAID ACE/ITN/TrialNet DSMB will formally review the safety data at least 
yearly.  The number of participants who discontinue study treatment will also be 
included in the reports prepa red for the DSMB.  
In addition, safety data will be reviewed by [CONTACT_185531], NIAID medical monitor, ITN physician, or the 
protocol chair to warrant review, or when an event occurs that contributes to a 
stoppi[INVESTIGATOR_185498] 3.5.2.  
Immune Tolerance Network  CONFIDENTIAL  Page 33 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   3.5.2 Stoppi[INVESTIGATOR_10020] s  
[IP_ADDRESS] Study-related Adverse Events  
If any of the following events occur, enrollment will be suspended and the DSMB 
chair will be notified such that a review of safety data will determine if enrollment in 
the study will be stopped and/or administration of investigational study medication 
should be halted:  
ÔÇ∑ Any death except those assessed as not related to study treatment on review by  [CONTACT_185532], and the DAIT, NIAID medical monitor.  
ÔÇ∑ Any demyelinating -related event . 
ÔÇ∑ Any gastrointestinal perforation.  
ÔÇ∑ Evidence of serious opportunistic infection, including tuberculosis , or EBV-
associated lymphoproliferative disorder . 
ÔÇ∑ Any grade 4 or higher infusion -related event.  
ÔÇ∑ Any unexpected, treatment -related SAE resulting in permanent treatment 
discontinuation and not related to glycemic events.  
ÔÇ∑ Three of the first 10 participants  or 30% thereafter,  in either age cohort,  require 
discontinuation of study medication for the same or similar serio us adverse event 
based on MedDRA preferred term or at the discretion of the DAIT , NIAID 
medical monitor . 
ÔÇ∑ Five of the first 10 participants, or 50% thereafter,  in either age cohort,  require 
discontinuation of study medication for individual stoppi[INVESTIGATOR_004], as defined in 
Section 5.3 (excluding pregnancy).  
4. ELIGIBILITY  
4.[ADDRESS_219045] meet  all of the following criteria to be eligible for this study: 
1. Male or female aged 6-45 years inclusive who meet the American Diabetes 
Association T1DM criteria.  
2. Diagnosis of T1DM within 100 days of enrollment  (V0). 
3. Positive for at least one diabetes -related autoantibody , including but not limited 
to: 
a) Glutamate decarboxylase (GAD -65); 
b) Insulin, if obtained within 10 days of the onset of exogenous insulin therapy;  
c) IA-2; or 
d) ZnT8. 
Immune Tolerance Network  CONFIDENTIAL  Page 34 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   4. Peak stimulated C -peptide level ‚â• 0.2 pmol/mL following a MMTT conducted  at 
least 21 days from diagnosis and withi n 37 days of randomization  (V0). 
5. Signed informed  consent (and informed assent of minor, if applicable).  
4.2 EXCLUSION CRITERIA  
Patients who meet any of the following criteria will not be eligible for this study:  
1. Severe reaction or anaphylaxis to human, humanized or murine monoclonal 
antibodies.  
2. History of malignancy or serious uncontrolled cardiovascular, nervous system, 
pulmonary, renal, or gastrointestinal disease, or significant dyslipi[INVESTIGATOR_035].  
3. Any history of recent serious bacterial, viral, fungal, or other opportunistic 
infections.  
4. Have serologic evidence of current or past HIV, Hepatitis B, or Hepatitis C.  
5. Positive tuberculin skin test  ([COMPANY_003]) or QuantiFERON TB  test, history of 
tuberculosis, or active TB infection.  
6. Active infection with EBV as defined by [CONTACT_185517] ‚â• 10,000 copi[INVESTIGATOR_66487] 106 
PBMCs or ‚â• 2,000 copi[INVESTIGATOR_185489] . 
7. Active infection with CMV as defined by [CONTACT_185518] ‚â• 10,[ADDRESS_219046], 
or both > 1.5 x the upper  limit of age -determined normal (ULN) or total bilirubin 
> ULN. 
9. Current or prior treatment that is known to cause a significant, ongoing change in 
the course of T1D or immunologic status.  
10. Current or prior (within last 14 days of screening MMTT visit ) use of drugs other 
than insulin  to treat hyperglycemia (e.g. metformin, sulfonylureas, glinides, 
thiazolidinediones, exenatide, liraglutide, DPP -IV inhibitors, or amylin).  
11. Current use of any medication known to significantly influence glucose tolerance 
(e.g., atypi[INVESTIGATOR_16709], diphenylhydantoin, niacin).  
12. Any of the following hematologic abnormalities, confirmed by [CONTACT_67753]:  
a. White blood count <3,000/ŒºL or >14,000/ŒºL;  
b. Lymphocyte count <500/ŒºL;  
c. Platelet count <150,000 /ŒºL;  
Hemoglobin <8.5 g/dL; or  
d. Neutrophil count <2,000 cells/ŒºL.  
13. Females who are pregnant, lactating, or planning on pregnancy during the 2 -year 
study period.  
Immune Tolerance Network  CONFIDENTIAL  Page 35 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   14. History or diagnoses of other autoimmune disease s with the exception of stable 
thyroid or celiace disease . 
15. History of alcohol, drug or chemical abuse within 1 year prior to screening  (V-1). 
16. Any medical or psychological condition that in the opi[INVESTIGATOR_185499].  
17. Prior participation in a clinical trial that could increas e risks associated with this 
clinical trial.  
18. Receipt of live vaccine (e.g. varicella, measles, mumps, rubella, cold -attenuated 
intranasal influenza vaccine, bacillus Calmette -Gu√©rin, and small pox) in the 6 
weeks before randomization  (V0). 
19. High lipid levels (fasting LDL  cholesterol ‚â•160 mg/dL  or ‚â•4.1mmol/L ). 
20. History of significant allergy (e.g. anaphylaxis) to milk or soy proteins.  
4.[ADDRESS_219047] to 
follow-up.   
Investigator judgment. A severe or serious AE occurs, which, based on the medical 
judgment of the investigator, prevents completion of participation for study treatment . 
If study treatment is discont inued, the DAIT, NIAID medical monitor should be 
notified.  If feasible and medically appropriate, subjects will be asked to continue in 
safety and outcome assessments and visits.   
5. STUDY MEDICATION S 
5.1 INVESTIGATIONAL MEDICATION  
ACTEMRA¬Æ (tocilizumab) is the investigational agent  and will be provided  to the 
clinical research sites by [CONTACT_1034] .  For sites in the US, commercially -labeled 
licensed product will be obtained by [CONTACT_185533] 
(Genentech , Inc. a member of the [COMPANY_002] g roup, located in South San Francisco, CA ) 
or acquired from commercial sources.  For sites in Australia, commercially labeled 
licensed ACTEMRA¬Æ (tocilizumab ) will be obtained through each  site pharmacy  
from commercial sources.   
Saline from clinical site pharmacies will be used as placebo  in this Protocol. 
Immune Tolerance Network  CONFIDENTIAL  Page 36 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   5.1.1 Formulation  and Packaging  
 
 
 
 
 
 
 
5.1.2 Reconstitution   
5.1.3 Dosage, Preparation, and Administration  
For those with weight ‚â• 30 kg, tocilizumab will be administered at a dose of 8 mg/kg 
every four weeks as an IV infusion not to e xceed 800 mg.  For those with weight < 30 
kg, tocilizumab  will be administered at a dose of 10 mg/kg.  Dosing will be according 
to the individual‚Äôs weight and the value will be rounded up by [CONTACT_185534]; i.e. 45.6 kg weight will be rounded up to 46 kg.  Weight from the previous 
visit or current visit may be used.  If the previous visit  was more than three months 
ago or if there is more than 10% change in body weight  from previous dose, then,  
dosing of study drug will be calculated according to the individual‚Äôs weight on the day 
of the visit .  
For subjects <30 kg at the start of the trial and if their weight increases above 30 kg 
and is also greater than 10% from the start of the trial, their current weight will be 
used to calculate tocilizumab dose based on 8 mg/kg, otherwise the 10 mg/kg will 
continue to be used.   
Tocilizumab should be administered intravenously over approximately  60 minutes .  
Subjects will be observed in the clinic for  15 minutes after the end of the infusion.   
Vital signs (blood pressure and pulse) will be recorded within 10 minutes before, 15 
minutes during, at the end, and within 15 minutes after completion of each infusion.   

Immune Tolerance Network  CONFIDENTIAL  Page 37 
Protocol ITN058AI: Greenbaum  Version 6.[ADDRESS_219048] been observed  following treatment 
with TCZ in combination with MTX.   
The risk mitigation strategies for neutropenia and thrombocytopenia are summarized 
in Table 2 and Table 3 , respectively.  
Table 2. Neutropenia Risk Mitigation  
ANC (cells/ ¬µL) Action 
> 1,000 Maintain dose.  
500 ‚Äì 1,000 Interrupt tocilizumab dosing  and recheck ANC as clinically 
relevant.  
When ANC increases to > 1 ,000, resume tocilizumab  at the 
next expected 4 week interval .  The overall course of study 
treatment will not be extended and missed doses will not be 
administered.  If the adverse event does not resolve in 8 
weeks, discontinue study treatment permanently.  
One suspension due to neutropenia is allowed during the 
treatment period.  
< 500 Discontinue tocilizumab.   
ANC = absolute neutrophil count  
Table 3. Thrombocytopenia Risk Mitigation  
Platelet count (cells/ ¬µL) Action 
> 100,000  Maintain dose.  
50,000 ‚Äì 100,000 Interrupt tocilizumab dosing  and recheck platelet count as 
clinically relevant .  
When platelet count increases to > 100,000, resume 
tocilizumab  at the next expected 4 week interval.  The 
overall course of study treatment will not be extended and 
missed doses will not be administered.   If the adverse event 
does not resolve in 8 weeks, discontinue study treatment 
permanently.   One suspension due to thrombocytopenia is 
allowed during the treatment period.  
< 50,[ADDRESS_219049] are summarized in Table 4. 
Immune Tolerance Network  CONFIDENTIAL  Page 38 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   Table 4. Liver Function Tests Risk Mitigation  
ALT/AST  Action 
< 3xULN  Maintain dose.  
>3xULN to <[ADDRESS_219050] Interrupt tocilizumab dosing and recheck  ALT/AST  as 
clinically relevant.  
When ALT/AST decreases to <3xULN, resume tocilizumab  
at the next expected 4 week interval.  The overall course of 
study treatment will not be extended and missed doses will 
not be administered.   If the adverse event does not resolve in 
8 weeks, discontinue study treatment permanently.  One 
suspension due to  elevated ALT/AST is allowed during the 
treatment period.  
> 5xULN  Discontinue tocilizumab.  
 
The recommended dose modification strategies for elevations in bilirubin are 
summarized in Table 5. 
Table 5. Elevated Total Bilirubin Risk Mitigation  
Total Bilirubin  Lab Values Action 
> 3 mg/dL  For increases in this range, tocilizumab dosing  will be stopped 
permanently .  Recheck total bilirubin as clinically relevant.  
5.2.[ADDRESS_219051] who develops infection or  
reactivation of EBV or CMV, as defined by [CONTACT_67792]; or if the EBV 
viral load is ‚â• 10,000 copi[INVESTIGATOR_66487] 106 PBMCs or ‚â• 2,000 copi[INVESTIGATOR_185500] ‚â• 10,000 IU or copi[INVESTIGATOR_185501] , will 
not receive additional study drug until resolution  of active infection.   
The overall course of study treatment will not be extended and missed doses will not 
be administered.  One suspension due to infection is allowed .  If a second suspension 
due to infectio n occurs during the treatment period, then discontinue study treatment 
permanently.  
Tocilizumab should be stopped permanently  if a patient develops a serious infection, 
an opportunistic infection, or sepsis.  A patient who develops a new infection during 
treatment with tocilizumab should undergo a prompt and complete diagnostic workup 
appropriate for an immunocompromised patient, appropriate antimicrobial therapy 
should be initiated, and the patient should be closely monitored.  Patients should be 
closely m onitored for signs and symptoms of tuberculosis.  
Immune Tolerance Network  CONFIDENTIAL  Page 39 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   5.2.5 Elevated Lipi[INVESTIGATOR_185502] ‚â•160 
mg/dL or ‚â•4.1 mmol/L .  Subjects with LDL values between 100 and 160 may be 
considered for treatment with lipid lowering agents.   
5.2.6 Hypersensitivity or Anaphylaxis   
An infusion/dose reaction is defined as an adverse event occurring during and within 
24 hours after the infusion o r subcutaneous injection of tocilizumab.  This may 
include hypersensitivity reactions or anaphylactic reactions.  
Signs of a possible hypersensitivity reaction include but are not limited to:  
ÔÇ∑ Fever, chills, pruritus, urticaria, angioedema, and skin rash.  
ÔÇ∑ Cardiopulmonary reactions, including chest pain, dyspnea, hypotension or 
hypertension.  
If a patient has symptoms of anaphylaxis or hypersensitivity, or requires an 
interruption of the study drug because of symptoms of anaphylaxis or 
hypersensitivity, admin istration of TCZ must be discontinued permanently.  The 
patient should be treated according to the standard of care for management of the 
hypersensitivity reaction.  
5.3 DISCONTINUATION OF S TUDY MEDICATION IN A N INDIVIDUAL 
PARTICIPANT  
The dosing and administra tion of investigational medication according to study 
specification will be discontinued for an individual participant if any of the following 
criteria is met:  
ÔÇ∑ Anaphylaxis  or hypersensitivity  reaction. 
ÔÇ∑ A confirmed demyelinating  event. 
ÔÇ∑ Gastrointestinal perf oration. 
ÔÇ∑ Malignancy . 
ÔÇ∑ Adverse events requiring study drug discontinuation as defined in section 5.2.  
ÔÇ∑ The investigator determines that it is in the participant‚Äôs best interest to 
discontinue treatment.  
ÔÇ∑ The participant, or participant‚Äôs legal representative, requests that treatment be 
halted. 
ÔÇ∑ The participant becomes pregnant.  
Further care will be provided according to the judgment and practice of the 
investigator.  
Immune Tolerance Network  CONFIDENTIAL  Page 40 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   The participant will be asked to remain in the study and participate in follow -up.  If 
study treatment is discontinued, the DAIT, NIAID medical monitor should be 
notified. 
5.4 CONCOMITANT MEDICATI ONS 
5.4.1 Prohibited Medications  
Participants will be instructed  not to use the following medications : 
ÔÇ∑ Agents that  are known to significantly  influence i nsulin sensitivity or secretion.  
ÔÇ∑ Medications known to affect the laboratory measurement of C -peptide (i.e. 
Strensiq¬Æ (asfotase alfa)).  
ÔÇ∑ Non-insulin pharmaceuticals for glycemic control . 
ÔÇ∑ Live vaccine (varicella, measles, mumps, rubella, cold -attenuated intra nasal 
influenza vaccine, bacillus Calmette -Gu√©rin, and smallpox) 6 weeks before 
enrollment, during study drug administration, and within 3 months after 
completing study drug.  
ÔÇ∑ Agents that may result in immunosuppression or immunomodulation, including  
chronic and persistent use of  inhaled, extensive topi[INVESTIGATOR_185503].  
If a participant receives, or if the investigator believes that a participant must receive, 
a prohibited medication, the case must be immediately discussed with the prot ocol 
chair, the DAIT, NIAID medical monitor, and the ITN clinical trial physician.  
The use of prohibited medications must be documented on the source document and 
CRF.  
5.5 DRUG ACCOUNTABILITY  
Under US code of federal regulations (21CFR 312.62) , Australian TGA regulations 
and ICH E6 Good Clinical Practice  guidelines, an investigator is required to maintain 
adequate records of the disposition of the investigational product, including the date 
and quantity of drug that was received, the participants to whom drug  was dispensed 
(participant by [CONTACT_80934]), and an account of any drug accidentally or 
deliberately destroyed.   The investigator will ensure that the investigational product 
supplies are stored as specified in the protocol and pharmacy manual i n a secured 
area, with access limited to authorized study personnel as described in the clinical 
study agreement.  
Records for receipt, storage, use, and disposition of the study drug will be maintained 
by [CONTACT_80935].  A drug -dispensing log will be kep t current for each participant and 
will contain the identification of each participant and the date and quantity of drug 
dispensed.   All remaining unused investigational product will be returned to the 
Immune Tolerance Network  CONFIDENTIAL  Page 41 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   Global Study sponsor (DAIT, NIAID , NIH) or sponsor‚Äôs r epresentative after study 
termination, or destroyed with the permission of the sponsor in accordance with 
applicable law and study site procedures.  If investigational product is to be destroyed 
locally, the investigator will provide documentation in accor dance with sponsor‚Äôs 
specifications.  
All records regarding disposition of the investigational product will be available for 
inspection by [CONTACT_93243].  
5.6 ASSESSMENT OF COMPLI ANCE WITH STUDY MEDI CATION  
Tocilizumab will be administered intravenou sly by [CONTACT_185535]; compliance, 
therefore, will be monitored by [CONTACT_185536].  
6. STUDY PROCEDURES  
6.1 INTENSIVE DIABETES M ANAGEMENT  
During the study period, all participants will receive ‚Äúintensive‚Äù management of their 
diabetes, and HbA 1C will be assessed at every visit  to evaluate metabolic control.  The 
goal of treatment will be to maintain the HbA 1C levels within the currently 
recommended ADA age -specific target ranges in the absence of significant or severe 
hypoglycemia.  The primary responsibility for diabetes management will be the 
treating or referring diabetes care provider, but the research study team will p rovide 
close additional support through regular interaction.  Glucose levels should be 
checked frequently and records communicated regularly to the study team.   
6.2 VISIT WINDOWS  
6.2.1 Scheduled Visits  
The initial treatment should begin within 100 days from the day  of diagnosis and 
within 37 days of the screening MMTT.  Subsequent treatment visits are every 4 
weeks.  The treatment visits (V0 -V6) must occur within [ADDRESS_219052], no one will receive more than 7 doses over the 6 month 
period.  The window for all subsequent visits is +/ - 2 weeks.  Appendix 1 pr esents the 
schedule of events for this trial.   
6.3 RANDOMIZATION , MASKING , AND UNMASKING  
6.3.1 Randomization  
Participants who sign the informed consent and meet the eligibility criteria will be 
randomly assigned in a 2:1 ratio to either the experimental or control  group.  A central 
automated randomization system will be used for treatment assignment and to create a 
unique identifier for each new study participant.  Adults and children will be 
Immune Tolerance Network  CONFIDENTIAL  Page 42 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   randomized separately.  For subjects in the adult cohort, random assignme nt will be 
stratified by [CONTACT_3725].  For subjects in the child cohort, random assignment will be 
stratified by [CONTACT_185537] 2 -hour C-peptide AUC (< 0.53, 0.53 -0.79, >0.79 
pmol/ml).   
Note that the cutpoints for the baseline mean 2-hour AUC levels are the tertiles 
observed in a sample that included 104 placebo subjects aged 6 to 17 pooled across 5 
TrialNet studies.10,11,60-62 
6.3.2 Masking to treatment assignment  
Masking will be maintained throughout the study for all study participants and study 
personnel, except the pharmacists .   
6.3.3 Unmasking  
Unmasking before the study is completed will occur if a participant‚Äôs well -being is 
threatened and  the investigator believes unmasking is necessary to protect the 
participant.  Unmasking may also occur in the case of pregnancy (participant or 
partner preg nancy) at the request of the pregnant woman . 
Before treatment assignment for an individual participant  is unmasked, the 
investigator  should attempt  to confer with the DAIT medical monitor.  In the event 
that the DAIT medical monitor was not previously notified of the emergency 
unmasking,  the site investigator will notify the DAIT medical monitor and ITN 
physician of  an unmasking event as soon as possible after the fact.   
The emergency unmasking will be recorded  and reported to the DSMB.  A full 
account of the event will be recorded, including the date and time of the emergency, 
the reason for the decision to unmask, and the names of the medical monitor  and 
others who were notified of the emergency.   During site visits, the site monitor must 
verify that the DAIT medical monitor was notified and that a written account was 
completed .  The reasons for unmasking of a participant‚Äôs treatment will be included in 
the final study report.  
Unmasking will also oc cur for Safety Reports (S[LOCATION_003]Rs) that will be reported to the 
US and Australian Health Authorities , DSMB and IRBs /ECs as specified in the 
current FDA IND Safety Reporting guidance.  
ITN and DAIT, NIAID approval is required for unmasking the treatment of an 
individual participant or subgroups of participants for unplanned  interim analyses to 
support DSMB reviews and final analysis.   
6.4 GENERAL ASSESSMENTS  
ÔÇ∑ Informed consent: Written informed consent will be obtained from the participant 
before any study assessments or procedures are performed.  
Immune Tolerance Network  CONFIDENTIAL  Page 43 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   ÔÇ∑ Eligibility criteria: Eligibility for study participation will be assessed during the 
screening period.  
ÔÇ∑ Medical history : This includes T1DM time of diagnosis and clinically significant 
diseases or medical  procedures.   
ÔÇ∑ Adverse events : Participants will be assessed for AEs.  
ÔÇ∑ Concomitant medications : All concomitant medications and their indications will 
be recorded.  
ÔÇ∑ Physical examination : This may be a comprehensive or directed exam as noted in 
the SOE (Appendix 1). 
ÔÇ∑ Vital signs: Weight, temperature, blood pressure, respi[INVESTIGATOR_1516], and pulse will be 
obtained at all visits .  Height will be obtained at initial visits for all subjects and 
every 6 months for children.  
6.5 CLINICAL LABORATORY ASSESSMEN TS 
Clinical laboratory blood draws are to be performed after vital signs are assessed and 
prior to study drug infusion during the treatment period.  Participants will periodically 
undergo blood draws for both clinical and immunologic tests.  Blood volumes drawn 
will be based on participant body weight and may be modified to limit the total blood 
volume drawn at any one visit.  
Central laboratory assessments:  
ÔÇ∑ Serum chemistries : Electrolytes (sodium, potassium, chloride, phosphate, total 
CO2), blood urea nitrogen (BUN), cr eatinine, CRP and liver panel (AST, ALT, 
alkaline phosphate, direct and total bilirubin).  
ÔÇ∑ Hematology : Includes RBC, hematocrit, hemoglobin, platelet count, WBC and 
differential.  
ÔÇ∑ Lipid panel: Total cholesterol, HDL, LDL, triglycerides.  
ÔÇ∑ Urinalysis: Includes blood (RBCs), glucose, ketones, pH, protein and specific 
gravity. 
ÔÇ∑ Infectious disease serology: Serology will be performed at screening for HBV, 
HCV, HIV, EBV, CMV.   CMV or EBV s erology will be repeated if participants 
show clinical signs of infection; or if the EBV viral load is ‚â• 10,000 copi[INVESTIGATOR_66487] 106 
PBMCs or ‚â• 2,000 copi[INVESTIGATOR_185504] ‚â• 
10,000 IU or copi[INVESTIGATOR_185501] . 
ÔÇ∑ Viral load testing: Viral load testing by [CONTACT_185538].  
ÔÇ∑ TB test: Exposure to tuberculosis will be assessed via QuantiFERON TB test  (A 
[COMPANY_003] skin test  may be performed locally if the QuantiFERON TB test is not 
performed at the central lab). 
Immune Tolerance Network  CONFIDENTIAL  Page 44 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   ÔÇ∑ Serum Œ≤HCG: Serum testing will be performed at screening to rule out pregnancy.  
Serum Œ≤HCG will be repeated after screening for participants with a positive urine 
HCG result at any study visit.  
Disease-Specific Assessments:  
ÔÇ∑ C-peptide (as part of MMTT).  
ÔÇ∑ Plasma glucose (as part of M MTT and FSIVGTT ). 
ÔÇ∑ Insulin (as part of FSIVGTT).  
ÔÇ∑ HbA1c 
ÔÇ∑ Diabetes-related autoantibodies  
Drug-Related Assessments:  
ÔÇ∑ Pharmacokinetics (PK)  
ÔÇ∑ IL-6 and IL-6sR 
ÔÇ∑ Anti-TCZ antibod ies 
Laboratory assessments evaluated at the site:  
ÔÇ∑ Urine HCG : Urine HCG will be measured before study drug administration 
during the treatment period for female participants with reproductive capacity to 
monitor for pregnancy  
6.[ADDRESS_219053] PK samples taken at the time  points listed in Table 6. 
Table 6: Pharmacokinetic Samples 
 
Visit # Time Points  
Day of Infusion  7 Days (Post infusion)  
V0 
(Week 0)  ÔÇ∑ before infusion  
ÔÇ∑ within 10 minutes after infusion  ÔÇ∑ 7 (¬±3) days after infusion  
V1 
(Week 4)  ÔÇ∑ before infusion   
V5 
(Week 20)  ÔÇ∑ before infusion  
ÔÇ∑ within 10 minutes after infusion  ÔÇ∑ 7 (¬±3) days after infusion  
V6 
(Week 24)  ÔÇ∑ before infusion   
 
Immune Tolerance Network  CONFIDENTIAL  Page 45 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   6.7 METABOLIC  ASSESSMENTS  
ÔÇ∑ MMTT:  A 2-hour MMTT is to be performed at weeks 12, 24, 39, and 78.  A 4-
hour MMTT is to be performed at week s -1 (screening), 52, and 104 for  subjects 
‚â•12 years old ( for subjects <12 years old, a 2 -hour MMTT will be performed 
instead.  
ÔÇ∑ HbA1c 
ÔÇ∑ Glucose (glucometer readings)  
ÔÇ∑ Continuous glucose monitoring (CGM)  to obtain data to evaluate glycemic 
control; particularly frequency  of hypoglycemia.  Randomized participants will be 
invited to use a commercially available FDA or appropriate Health Authorities  
approved CGM system  and its components (Dexcom, Inc., San Diego, C A) for a 
14 day period at weeks 0, 12, 24, 52, 78, and 104.  Data may also be obtained for 
the study from the participant ‚Äôs CGM system if used as part of their usual clinical 
care. 
ÔÇ∑ Insulin use (U/kg body weight/day)  
ÔÇ∑ Major hypoglycemi c events 
ÔÇ∑ FSIVGTT (Frequently sampled glucose tolerance test).  To obtain additional 
information about the possible effects of therapy on insulin sen sitivity, a 
FSIVGTT will be offered to subjects age ‚â•[ADDRESS_219054] of the protocol, while remaining in the main study.  
Those who do participate will receive compensation f or their time and effort.  
6.8 MECHANISTIC ASSESSME NTS 
Mechanistic samples drawn during the study drug treatment period are collected prior 
to study drug infusion.  See section 7 for detailed discussion of additional mechanistic 
assays. 
7. TOLERANCE ASSAYS 
7.1 MECHAN ISTIC HYPOTHESIS  
The primary mechanistic hypotheses are that anti -IL6R therapy in T1D will promote 
T regulatory cell activity, suppress innate immune responses, and alter B cell activity .  
Studies will address multiple questions but will be  prioritized bas ed on the amount of 
blood available.  Questions to be addressed in current rank order are:  
ÔÇ∑ Anti-IL6R results in increased numbers of the peripheral regulatory T cell 
population and diminishes numbers of pro -inflammatory T cells, including Th17 
cells. 
Immune Tolerance Network  CONFIDENTIAL  Page 46 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   ÔÇ∑ Anti-IL6R results in altered functional status of both regulatory T cells and pro -
inflammatory T cells .    
ÔÇ∑ Anti-IL6R enhances the sensitivity of effector T cells to suppression by  [CONTACT_185539]. 
ÔÇ∑ Anti-IL6R alters the proportions of circulating B cell compartment.  
ÔÇ∑ Anti-IL6R alters innate immune responses, including changes in the composition 
and activation of monocytes, dendritic cells, and NK cells.  
7.[ADDRESS_219055] fails to occur, the assays 
performed by [CONTACT_185540].  Specimens and data may be used for future 
research related  to diabetes and autoimmune diseases.  
7.2.1 Sample Types  
Samples will be collected under the auspi[INVESTIGATOR_185505]  (Appendix 1) . 
7.3 MECHANISTIC ASSAYS  
The following assay methodologies may be used to address the mechanistic 
hypotheses:  
ÔÇ∑ Multi-chromatic flow cytometry on banked PBMCs to monitor the changes in 
number and phenotype of various immune cell subsets including T cells, B cell 
subsets and innate cells.  Flow cytometry may also be used to assess the 
functional status of cells in re sponse to ex vivo stimuli for example, 
phosphorylated status of STAT proteins (STAT -3 or STAT5) and intracellular 
cytokine secretion.  
ÔÇ∑ Multiplex immunoassays may be used to measure changes in circulating markers 
using serum or plasma collected at multiple time points during therapy . 
Immune Tolerance Network  CONFIDENTIAL  Page 47 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   ÔÇ∑ Cell-based proliferation assays may be used to examine the changes in resistance 
to Treg-mediated suppression of Teff cells using viably frozen PBMCs . 
ÔÇ∑ Epi[INVESTIGATOR_185506] , Th17, Th1 and Tfh  cell numbers .   
ÔÇ∑ One or more gene expression analysis platforms may be used to evaluate changes 
in expression of various genes using blood frozen in presence of RNA stabilizing 
agents. 
ÔÇ∑ Genetic variation a nd SNP analysis of genes of interest may be performed on 
DNA isolated from frozen whole blood.                
ÔÇ∑ Other assays as approved by [CONTACT_185541].   
8. ADVERSE EVENTS 
8.1 OVERVIEW  
The investigator is responsible for the detection and documentation of events meeting 
the criteria and definition of an AE (adverse event) or SAE (serious adverse event) as 
described in Section 8.2 in this protocol. All AEs and SAEs will be recorded in the  
source documents and on the appropriate electronic CRF(s).  All data will be reviewed 
periodically by [CONTACT_4318], which may provide recommendations to NIAID about 
withdrawing any participant and/or terminating the study because of safety concerns.  
Adverse e vents that are classified as serious according to the definition of Health 
Authorities must be reported promptly and appropriately to the Global Study Sponsor  
(DAIT, NIAID, NIH), ITN, principal investigators in the trial, IRBs /ECs, and 
appropriate Health Authorities .  This section defines the types of AEs and outlines the 
procedures for appropriately collecting, grading, recording, and reporting them.  
Information in this section complies with 21CFR 312; ICH Guideline E2A : Clinical 
Safety Data Management: D efinitions and Standards for Expedited Reporting; and 
ICH Guideline E -6: Guidelines for Good Clinical Practice;  and applies the standards 
set forth in the National Cancer Institute‚Äôs Common Terminology Criteria for Adverse 
Events Version 4.0 3 (published June 14, 2010 ) with the exception of reporting of 
hyperglycemia and hypoglycemia as noted below .  This document referred to h erein 
as the ‚ÄúNCI -CTCAE manual .‚Äù  
8.2 DEFINITIONS  
8.2.1 Disease -specific Adverse Event  
For the purposes of this study, major hypoglycemi c events will be recorded in the 
eCRF.  Major hypoglycemic e vents are defined as:  
ÔÇ∑ Blood glucose concentration < 40  mg/dL; (Grades 3‚Äì5, NCI-CTCAE version 
4.03), or  
Immune Tolerance Network  CONFIDENTIAL  Page 48 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   ÔÇ∑ Hypoglycemi c events involving seizure or loss of consciousness (coma), or 
requiring assistanc e from another individual in order to recover.  
All epi[INVESTIGATOR_185507]/or emergency care will 
be reported to the DSMB in an expedited manner as described in Section 8.5.3.    
8.2.2 Adverse Event  
An adverse event (AE) is any occurrence or worsening of an undesirable or 
unintended sign, symptom, laboratory finding, or disease that occurs during 
participation in the trial.  An AE will be followed until it resolves or until [ADDRESS_219056].  All AEs will be 
reported as specified in Section 8.3.1 whether they are or are not related to disease 
progression or study participation.  
8.2.3 Suspected Adverse Reaction and Adverse Reaction  
Suspected adverse reaction (SAR) means any adverse event for which there is a 
reasonable possibility that the study drug caused the adverse event.  For the purposes 
of safety reporting, ‚Äòreasonable possibility‚Äô means there is evidence to suggest a 
causal relationship between the drug and the adverse reaction.  A suspected adverse 
reaction implies a lesser degree of certainty about causality than adverse reaction, 
which means any adverse event caused by a drug (21 CFR 312.32(a)) /(ICH E2A) . 
An adverse reactio n (AR) means any adverse event caused by a study drug.  Adverse 
reactions are a subset of all suspected adverse reaction for which there is reason to 
conclude that the drug caused the event.  
8.2.4 Serious Adverse Event  
An AE or SAR is considered ‚Äúserious‚Äù if, i n the view of either  the investigator or 
DAIT, NIAID it results in any of the following outcomes (21 CFR 312.32(a)) /(ICH 
E2A): 
ÔÇ∑ Death: A death that occurs during the study or that comes to the attention of the 
investigator during the protocol -defined follow -up period must be reported 
whether it is considered treatment related or not.  
ÔÇ∑ A life-threatening event: An AE or SAR is considered ‚Äúlife -threatening‚Äù if, in the 
view of either the investigator or DAIT , NIAID, its occurrence places the subject 
at immediate  risk of death.  It does not include an AE or SAR that, had it occurred 
in a more severe form, might have caused death.  
ÔÇ∑ Inpatient hospi[INVESTIGATOR_1081].  
ÔÇ∑ Persistent or significant incapacity or substantial disruption o f the ability to 
conduct normal life functions.  
Immune Tolerance Network  CONFIDENTIAL  Page 49 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   ÔÇ∑ An event that requires intervention to prevent permanent impairment or damage. 
An important medical event that may not result in death, be life threatening, or 
require hospi[INVESTIGATOR_185508], based on appropriate 
medical judgment, it may jeopardize the participant and may require medical or 
surgical intervention to prevent one of the outcomes listed above.  
ÔÇ∑ Congenital anomaly or birth defect.  
8.2.[ADDRESS_219057] (AESIs)  
Adverse Events of Special Interest (AESIs) are identified for  ACTEMRA¬Æ 
(tocilizumab) and will be collected and reported as study-specific AEs or SAEs in 
this trial.  Investigators should use their clinical judgement to identify events falling in 
any of the following categories : 
ÔÇ∑ Opportunistic and serious infections (including all opportunistic infections and all 
non-serious infections as defined by [CONTACT_185542] -infectives ).  
ÔÇ∑ Myocardial inf arction/acute coronary syndrome.  
ÔÇ∑ Gastrointestinal perfora tions and related events,  including  complications of 
diverticulitis, appendicitis, generalized purulent peritonitis, lower GI perforation, 
fistula, and/or abscess . 
ÔÇ∑ Anaphylaxis (and/or related hypersensitivity reactions  that require treatment 
discontinuatio n).  
ÔÇ∑ Malignancies.  
ÔÇ∑ Hepatic Events,  including elevated hepatic transaminase levels (ALT/AST levels 
> 3ÔÇ¥ ULN) or total bilirubin > 3 mg/dL . 
ÔÇ∑ Bleeding Events,  including any clinical  sign of hemorrhage that requires 
diagnostic studies, hospi[INVESTIGATOR_059], and/or treatment .  
ÔÇ∑ Stroke, including ischemic or hemorrhagic stroke, or transient ischemic attack .  
ÔÇ∑ Demyelinating disorders  (with signs or symptoms  of a demyelinating disorder  
such as multiple sclerosis or chronic inflammatory demyelinating 
polyneuropathy ). 
If an adverse event meets any of the above study -specific categories , regardless of the 
relationship of the event to study drug  or severity , the event must be reported to the 
Global Study Sponsor (DAIT, NIAID, NIH) as described in Section 8.5.1.   For all 
Adverse Events of Special Interest received by [CONTACT_185543] (serious and 
non-serious), a guided questionnaire  will be used to obtain follow -up information.  
Immune Tolerance Network  CONFIDENTIAL  Page 50 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   8.2.6 Unexpected Adverse Reaction  
A SAR is considered ‚Äúunexpected‚Äù when its nature (specificity), or  severity, or rate of 
occurrence is not consistent with applicable product information as described in the 
safety information provided in the developmental core safety information section of 
the current F. Hoffman La -[COMPANY_002] LTD Investigator‚Äôs Brochure and country-specific 
package inserts for tocilizumab . 
8.3 COLLECTING AND RECOR DING ADVERSE EVENTS  
8.3.1 Methods of Collection  
All adverse events  (AEs) will be collected and recorded from visit -1 until the time the 
participant completes the study, or prematurely withdra ws from the study .  All serious 
adverse events (SAEs) will be collected from visit -1 until 30 days after the participant 
completes the study, or 90 days after the participant prematurely withdraws from the 
study.  
Adverse events and serious adverse events  may be collected as follows:  
ÔÇ∑ Observing the participant.  
ÔÇ∑ Questioning the participant in an objective manner.  
ÔÇ∑ Receiving an unsolicited complaint from the participant.  
An AE that is an asymptomatic abnormal value or result from a clinical or laboratory 
evaluation (e.g., a radiograph, an ultrasound, or an electrocardiogram) will be 
documented and maintained in the source records.  Asymptomatic adverse events 
must be recorded on the AE form when they meet the criteria for a Grade 3 or greater 
AE per CTCAE crite ria, with the exception of AESIs (Section 8.2.5)  and 
hyperglycemia and hypoglycemia as defined in Section 8.4.1 .  The evaluation that 
produced the value or result should be repeated until that value or result returns to 
normal or can be explained and the p articipant‚Äôs safety is not at risk.  
8.3.[ADDRESS_219058] medical terminology/concepts should be used when reporting AEs and SAEs. 
Avoid colloquialisms and abbreviations.  
ÔÇ∑ Diagnosis vs. Signs and Symptoms  
If known at the time of reporting, a diagnosis should be reported rather than 
individual signs and symptoms (e.g., record only liver failure or hepatitis rather 
than jaundice, asterixis, and elevated transaminases).   However, if a constellation 
of signs an d/or symptoms cannot be medically characterized as a single diagnosis 
or syndrome at the time of reporting, it is ok to report the information that is 
currently available.  If a diagnosis is subsequently established, it should be 
reported as follow -up information. 
Immune Tolerance Network  CONFIDENTIAL  Page 51 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   ÔÇ∑ Deaths 
All deaths that occur during the protocol -specified AE reporting period (see 
Section 5.1.2), regardless of attribution, will be reported to the appropriate parties.   
When recording a death, the event or condition that caused or contributed to the 
fatal outcome should be reported as the single medical concept.  If the cause of 
death is unknown and cannot be ascertained at the time of reporting, report 
‚ÄúUnexplained Death.‚Äù  
ÔÇ∑ Preexisting Medical Conditions  
A preexisting medical condition is one that is present at the start of the study. 
Such conditions should be reported as medical and surgical history.  A preexisting 
medical condition should be re -assessed throughout the trial and reported as an 
AE or SAE o nly if the frequency, severity, or character of the condition worsens 
during the study.  When reporting such events, it is important to convey the 
concept that the preexisting condition has changed by [CONTACT_13665] (e.g., ‚Äúmore frequent headaches‚Äù).  
ÔÇ∑ Hospi[INVESTIGATOR_164363].  If a subject is hospi[INVESTIGATOR_9615] a 
medical or surgical procedure as a result of an AE, the event responsible for the 
procedure, not the procedure itself, should be reported as the SAE.  For example, 
if a subject is hospi[INVESTIGATOR_15428], record the heart 
condition that necessitated the by[CONTACT_185544]. 
8.3.[ADDRESS_219059] all symptomatic AEs on the 
appropriate eCRF regardless of their severity or relation to study participation  and 
asymptomatic AEs of grade 3 or above .  The investigator will treat partic ipants 
experiencing AEs appropriately and observe them at suitable intervals until their 
symptoms resolve or their status stabilizes.  
8.3.4 Recording SAEs  
Serious AEs will be recorded on the SAE eCRF and Health Authorities will be 
notified as outlined in Section  8.5. 
8.4 GRADING AND ATTRIBUT ION OF ADVERSE EVENT S 
8.4.1 Grading of Major Hypoglycemic and Hyperglycemic Events  
For this study  of participants with type 1 diabetes , the NCI-CTCAE will not be used  
to grade hypoglycemia and hyperglycemia .  Please refer to the grading criteria for 
major hypoglycemic and hyperglycemic events below.  In this study, non -major 
hypoglycemic and hyperglycemic events will not be reported as AEs.  
Immune Tolerance Network  CONFIDENTIAL  Page 52 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   Major hypoglycemic events  will be graded as follows:  
ÔÇ∑ Grade 3 = blood glucose concentration < 40  mg/dL or <2.2 mmol/L ; (Grades 3 ‚Äì5, 
NCI-CTCAE version 4.0 3), or events resulting in seizures, loss of consciousness, 
or requiring the assistance of others for the purpose of altered consciousness.  
ÔÇ∑ Grade 4 = events resulting in c oma or life -threatening event requiring 
hospi[INVESTIGATOR_059].  
ÔÇ∑ Grade 5 = death.  
Major hyperglycemic  events will be graded as follows:  
ÔÇ∑ Grade 4 = coma or life -threatening event  or event resulting in hospi[INVESTIGATOR_059].  
ÔÇ∑ Grade 5 = death.  
For this study significant diabetic ketoacidosis (DKA) will be reported together with 
grade 4 hyperglycemia (as a single adverse event) resulting in hospi[INVESTIGATOR_185509].    
8.4.2 Grading for All Other Adverse Events  
The study site will grade the severity of A Es experienced by [CONTACT_185545]‚Äòs Common 
Terminology Criteria for Adverse Events ( NCI-CTCAE, v 4.03) manual and provides 
a common language to describe levels of severity, to analyze and interpret data, and to 
articulate the clinical significance of all AEs , with the exception of hypoglycemia and 
hyperglycemia.   
Adverse events will be graded on a scale from 1 to 5 according to the following 
standards in the NCI -CTCAE manual:  
ÔÇ∑ Grade 1 =  mild adverse event.  
ÔÇ∑ Grade 2 = moderate adverse event.  
ÔÇ∑ Grade 3 = severe and undesirable adverse event.  
ÔÇ∑ Grade 4 = life -threatening or disabling adverse event.  
ÔÇ∑ Grade 5 = death.  
For additional information and a printable version of the NCI -CTCAE manual, go t o 
http://ctep.cancer.gov/reporting/ctc.html .  
8.4.[ADDRESS_219060] the initial determination on the appropriate eCRF and/or 
SAE reporting form.  Infusion reactions occurring within 24 hours of starting study 
Immune Tolerance Network  CONFIDENTIAL  Page 53 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   drug infusion will be considered related to the study drug as defined in Section 5.2.6.  
The relation of an AE to study drug will be determined using definitions in Table 7.  
Final determination of attribution for safety reporting will be decided by [CONTACT_73884] , 
NIAID. 
Table 7. Attribution of Adverse Events  
8.5 REPORTING SERIOUS AD VERSE EVENTS  
8.5.1 Reporting SAEs to the Global Study Sponsor (DAIT, NIAID, NIH)   
The following process for reporting a SAE ensures compliance with 21CFR 312 and 
ICH guidelines. After learning that a participant has experienced a SAE, the 
investigator or designee will report the SAE via the electronic SAE report form (SAE 
eCRF) within [ADDRESS_219061] include the 
following:  
ÔÇ∑ AE term. 
ÔÇ∑ Study drug treatment . 
ÔÇ∑ Relationship to study medications.  
ÔÇ∑ Reason why the event is serious.  
ÔÇ∑ Supplementary CRF pages that are current at the time of SAE reporting: medical 
history, concomitant medications, demographics, study drug administration, death.  
As additional details become available, the SAE eCRF should be updated and 
submitted.   Every time the  SAE eCRF is submitted, it should be electronically signed 
by [CONTACT_185546].  Code Descriptor  Definition  
Unrelated Category  
1 Unrelated  The adverse event is clearly not related.  
2 Unlikely The adverse event is unlikely related.  
Related Categories*  
3 Possible The adverse event has a reasonable possibility to be related; there is 
evidence to suggest a causal relationship . 
4 Probable The adverse event is likely related. 
5 Definite The adverse event is clearly related. 
*Infusion reactions defined as fever, chills, pruritus, urticarial, angioedema, skin rash, anaphylaxis, 
and  cardiopulmonary reactions , not limited to chest pain, dyspnea, hypotension or hypertension, 
occurring within 24 hours of starting study drug infusion will be considered related to the study drug 
per section 5.2.6 
Immune Tolerance Network  CONFIDENTIAL  Page 54 
Protocol ITN058AI: Greenbaum  Version 6.[ADDRESS_219062] Safety:  
Rho Product Safety  
 
 
 
 
   
8.5.2 Reporting SAEs to Health Authorities  
After the SAE has been reported by [CONTACT_458] [INVESTIGATOR_185510] (DAIT, NIAID, NIH) .  In the US, the IND sponsor (DAIT, 
NIAID, NIH) must report an event to the FDA using one of these two options:  
ÔÇ∑ Standard reporting (re port in the IND annual report).  This option applies if 
the AE is classified as one of the following:  
o Serious, expected, suspected adverse reactions described in Sections 8.2.4 and 
8.2.5. 
o Serious and not a suspected adverse reaction described in Section 8 .2.3. 
ÔÇ∑ Expedited reporting is required. This option applies if the AE is classified as one 
of the following:  
o Serious and unexpected suspected adverse reactions described in Section 
8.2.3, and unexpected per Section 8.2.5.    
o The sponsor must report any suspected adverse reaction that is both serious 
and unexpected.  The sponsor must report an adverse event as a suspected 
adverse reaction only if there is evidence to suggest a causal relationship 
between the study drug and the adverse event, such as:  
ÔÇß A single occurrence of an event that is uncommon and known to be 
strongly associated with drug exposure (e.g., angioedema , hepatic 
injury, or Stevens -Johnson Syndrome) . 
ÔÇß One or more occurrences of an event that is not commonly associ ated 
with drug exposure, but is otherwise uncommon in the population 
exposed to the drug (e.g., tendon rupture) .  
o Aggregate analysis of specific serious adverse events observed in a clinical 
trial (such as known consequences of the underlying disease or co ndition 
under investigation or other events that commonly occur in the study 
population independent of drug therapy) that indicates those events occur 
more frequently in the drug treatment group than in a concurrent or historical 
control group . 

Immune Tolerance Network  CONFIDENTIAL  Page 55 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   o Any finding s from clinical or epi[INVESTIGATOR_9037], analysis of data pooled 
across multiple studies, published or unpublished scientific papers, or from 
animal or in vitro testing that would result in a safety -related change in t he 
protocol, informed consent, I nvestigator‚Äôs Brochure, or other aspects of the 
overall conduct of the trial will be reported.  
Safety reports must be reported by [CONTACT_73884] , NIAID to the FDA within 15 calendar days; 
fatal or immediately life -threatening, serious, unexpected, suspected adverse reactions 
must be reported within 7 calendar days.  
Australian Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) should be 
reported to the TGA by [CONTACT_185547]:  
ÔÇ∑ Fatal or life -threatening S[LOCATION_003]Rs: as soon as possible but no later than [ADDRESS_219063] knowledge, followed by [CONTACT_185548] a report as possible within 8 
additional calendar days.  
ÔÇ∑ All other serious S[LOCATION_003]Rs: as soon as possible but no later than [ADDRESS_219064] report SAEs to their respective IRBs /ECs as mandated 
by [CONTACT_476]. 
8.5.3 Reporting SAEs to the DSMB  
The Study Global Sponsor ( DAIT, NIAID , NIH) will provide the DSMB with data of 
all SAEs on a regular basis, including quarterly reports of all SAEs.   Major 
hypoglycemic events that require emergency care will also be reported to the DSMB 
in an expedited fashion regardless of whether they met the criteria for an SAE or not.  
8.5.4 Reporting of Adverse Events to IRBs/ECs  
All investigators must report adverse events, including expedited reports, in a timely 
fashion to their respective IRBs/ECs in accordance with applicable regulations and 
guidelines.  All Safety Reports to the FDA or the appropriate Health Authorities shall 
be distributed by [CONTACT_185549]/EC submission  according to local regulation and guidelines . 
8.5.[ADDRESS_219065] 
(AESIs) and SAEs on an ongoing basis as specified in the protocol -specific saf ety 
management plan  part B.   
 
Distribution as follows:  
1. DAIT SACC C (Rho Federal) will forward a notification including a copy of the 
eCRF of all SAEs  including significant follow -ups, AESIs, and pregnancies  to 
DAIT, NIAID and Genentech Drug Safety (GDS) within 24hrs of becoming 
aware of the event.  
Immune Tolerance Network  CONFIDENTIAL  Page 56 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   2. DAIT SACCC (Rho Federal)  will forward the final version of all SAEs , AESIs 
and pregnancies to Genentech , Inc. within 15 days of sponsor notification.  
3. All IND Safety Reports  with an Analysis of Similar Events will be sent to GDS at 
the time of transmission to the FDA.  
4. Any study report submitted to the FDA  by [CONTACT_13099] r should be copi[INVESTIGATOR_15436] , Inc.  This includes all IND annual reports and the Clinical Study 
Report (final study report).    
5. Final Reports format:  
a. For expedited reports: MedWatch  
b. For non-expedited related reports: Medical Summary Report  
c. AESIs: Event -Specific Guided Questionnaire  
d. All other non-serious AEs: Line listings  
6. DAIT SACC C (Rho Federal) statistician will post c umulative line listings of 
serious and non -serious AEs and pregnancy reports monthly to Rho  Portal. 
Genentech , Inc. will receive an email notificati on when the reports are posted or 
updated and will be able to access the study website to retrieve the listings as 
needed. 
8.5.6 Reporting Pregnancy  
The investigator should be informed immediately of any pregnancy in the participant 
or a partner pregnancy of a male participant occurring from randomization through  the 
end of the follow -up period (two -year study period).  A ll available pregnancy 
information should be entered into the electronic data capture (EDC) system within 24 
hours of becoming aware of the event.  The investigator should be available to counsel 
the participant or refer the participant (or partner) for counseling to  discuss the risks o f 
continuing with the pregnancy and the possible effects on the fetus .  The pregnant 
woman will have the option to be informed of treatment assignment should she wish 
to know.  She will be asked to sign a specific informed consent giving her approval 
for the site to monitor and report the conclusion of the pregnancy.  Follow -up 
information detailing the outcome of the pregnancy should be entered into the EDC 
system as it becomes available.  Any premature termination of the pregnancy would 
also be reported.  
Pregnancy will be recorded as an AE for tracking purposes.  Any pregnancy 
complication or elective termination of a pregnancy for medical reasons will be 
recorded as an AE or SAE as described in Sections 8.3.2 and 8.3.3.  
Immune Tolerance Network  CONFIDENTIAL  Page 57 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   9. STATISTICAL CONSIDERATIONS AND ANALYTICAL PLAN 
9.1   ANALYSIS SAMPLES  
Modified Intent to Treat (mITT) sample will include all randomized participants 
who received any dose of study treatment .  The efficacy analyses will be based on the 
mITT sample according to the group to which the partic ipants are assigned.  
Per protocol samples will be assessed for week 52 ( PP1) and week 104 ( PP2), and 
will include all participants in the mITT sample with no major protocol deviations that 
impact efficacy assessments, who have completed at least [ADDRESS_219066] 80% of the expected dose in each infusion, 
and who have the week [ADDRESS_219067]‚Äôs primary endpoint visit and the end of the study to 
determine which participants should be excluded from the per -protocol populations.  
Safety sample (SS) will be defined as all participants who received any degree of 
study trea tment.  Safety analyses will be based on actual treatment the participants 
receive. 
9.[ADDRESS_219068] will be 
conducted under the mITT  principle of eligible patients, whereby [CONTACT_185550].  
All analyses for the primary and secondary endpoints will be comple ted in the 
pediatric mITT sample  (ages 6 to 17 years) and will also be repeated on the pooled 
mITT sample (i.e. both adult and pediatric subjects) as secondary analyses.    
9.2.[ADDRESS_219069] the null hypothesis of ‚Äúno treatment group 
difference‚Äù versus the two -sided alternative using pediatric participants from the 
mITT sample.   The hypothesis test and baseline -adjusted treatment group estim ates 
will be derived from an ANCOVA model fit to the change in mean 2-hour C-peptide 
AUC response at week 52 with fixed effects for treatment group, baseline mean  2-
hour C-peptide AUC, and age.   Transformations of data will be considered if evidence 
of significant departures from model assumptions are apparent. 
Immune Tolerance Network  CONFIDENTIAL  Page 58 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   For a participant who misses the entire week 52 MMTT assessment, the missing AUC 
values will be imputed using the following approach for the primary analysis of the 
primary endpoint:  
ÔÇ∑ If the subject‚Äôs  last observed AUC value is 0, the missing week 52 AUC will be 
imputed to zero.  
ÔÇ∑ If the subject‚Äôs last observed AUC value was at time t and was >0, then the 
missing AUC at week 52 will be imputed using data from subjects in the same 
arm and age group who had available AUC values at both time t and week 52.   
Specifically, a linear regression line will be fit where week 52 AUC values are 
regressed on AUC values at time t (e.g. week 24). In each arm  and age group , a 
missing week 52 AUC value will be imputed as the value predicted from the 
linear regression line.  
At a minimum,  the following sensitivity analyses for the primary endpoint will be 
performed : 
ÔÇ∑ An analysis analogous to the primary endpoint analysis using only mITT subjects 
with observed data at week 52 (i.e., without imputing any missing week 52 AUC 
values). 
ÔÇ∑ An analysis analogous to the primary endpoint analysis using the PP1 subjects.  
ÔÇ∑ An analysis analogous to the primary endpoint analysis in the mITT sample using 
imputed values for missing week 52 AUC values as described  above but using a 
conservative approach.  In the active therapy arm, a missing week 52 AUC value 
will be imputed as the value predicted from the estimated lower limit of a 90% 
confidence band about  the linear regression line.  In the Control group, a missing 
week 52 AUC value will be imputed as the value predicted from the estimated 
upper limit of a 90% confidence band about the regression line.  
Note that, if research suggesting better methods for h andling missing C -peptide AUC 
data becomes available, changes to the above plan will be pre -specified in the 
Statistical Analysis P lan prior to data lock  and unmasking of treatment assignments 
for planned end -of-study analyses .  
9.2.2 Secondary Endpoints  
The null hypothesis proposes that there is no difference in the secondary endpoint 
(measured either as means or proportions) between study groups.  The alternative 
hypothesis proposes the opposite; that there is a difference in the secondary endpoints 
between the treatment and control groups.   All secondary inferential analyses are 
considered supportive; p -values will be presented without adjustment for multiple 
comparisons.  
Immune Tolerance Network  CONFIDENTIAL  Page 59 
Protocol ITN058AI: Greenbaum  Version 6.[ADDRESS_219070] modification by [CONTACT_185551] 2-hour C-peptide AUC 
and age will be evaluated.  In addition,  treatment groups will also be compared at 
weeks 12, 24, 39, and 52 using a random regression approach .  A random regression 
model will be fit to the mean 2-hour C-peptide AUC responses at baseline and weeks 
12, 24, 39, and 52 with fixed effects for treatment, time, age, and interactions for 
treatment*time and a ge*time.  Random within -subject effects for intercept and slopes 
over time will be included assuming an unstructured covariance matrix.   All subjects 
with at least [ADDRESS_219071] -baseline assessment will be included in the random regression 
model.  A separate rand om regression model will include C -peptide assessments 
through week 104.  For these models, pi[INVESTIGATOR_13959] -wise slopes will be considered to  allow 
for the potential rise and fall in mean 2-hour C-peptide. Transformations of data will 
be considered if evidence of si gnificant departures from model assumptions are 
apparent.  Alternative covariance structures will be considered if models fail to 
converge.  
Treatment group differences in the change in mean 4 -hour C-peptide AUC from 
baseline at weeks 52 and 104 will be com pared using ANCOVA analyses controlling 
for baseline.  ANCOVA models adjusting for baseline will also be used to analyze the 
change in peak 4 -hour C-peptide at weeks 52 and 104.  
In addition, a nalogous analyses  will be used to analyze glucose values, insulin use and 
HbA1c.   
The mechanistic hypothes is for secondary endpoint determination  (Section 3.3.2 ) is 
that the treatment will promote  Treg and/or reduce Teff cell frequency in the 
periphery .  Multi-chromatic flow cytometry will be used to monitor the frequency of 
Treg and Teff cell populations during the course of study  and the ratio of Treg/Teff 
will be determined  to investigate the  effect of T CZ on these cell types.  A linear mixed 
model analy sis will be used to evaluate Treg/Teff longitudinal differences  between 
control and treatment groups at week s 12, 24, 39, 52, 78 and 104. 
9.2.3 Safety Analysis  
Reports summarizing safety data will be prepared at the end of the study and 
periodically throughout t he study for re gulatory filings, the DSMB , and for the 
medical monitor and study management team. Safety reports will be prepared to meet 
the needs of those groups and individuals responsible for monitoring safety and may  
include (but are not limited to) masked summaries and listings of SAEs, AEs, changes 
in vital signs, events requiring drug discontinuations for individual subjects (See 
Section 5.3), and events listed as study stoppi[INVESTIGATOR_004] (Section [IP_ADDRESS]).  AEs and 
SAEs in the summary displays and lis tings will be coded using the MedDRA system 
organ classes and/or preferred terms.   Severity will be reported using NCI -CTCAE 
Immune Tolerance Network  CONFIDENTIAL  Page 60 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   grading criteria , with the exception of hypoglycemia and hyperglycemia .  
Relationship to study drug will be reported as per Section  8.4.2. 
The joint NIDDK and NIAID ACE/ITN/TrialNet DSMB will perform ongoing review 
of C-peptide data to monitor for unexpected declines, as follows :   
ÔÇ∑ For adult subjects,  mean 2-hour C-peptide AUC levels within 12 weeks of 
randomization will be reviewed o n an ongoing basis in a masked fashion for 
all subjects.  Once > 30% of randomized subjects are shown to have a mean 
2-hour C-peptide AUC at 12 weeks that is ‚â• 50% of their baseline mean 2 -
hour C-peptide AUC, monitoring may be discontinued.  However, if 70 % or 
more of the subjects show a > 50% drop in mean 2 -hour C-peptide AUC by 
[CONTACT_5875] 12, then the data will be unmasked by [CONTACT_185552], the percent of 
events in each arm will be computed, and the DSMB will be notified.  
ÔÇ∑ For pediatric subjects , mean 2-hour C-peptide AUC levels within [ADDRESS_219072] 
10 subjects with week 12 C -peptide data available in the active treatment 
group, the C -peptide data will be monitored using the followin g guideline.  If 
70% or more of the subjects in the active treatment group show a > 50% drop 
in mean [ADDRESS_219073] (see Section 3.3.2) will be 
compared using the Fisher‚Äôs Exact statistics.  
9.2.[ADDRESS_219074] 12 mo nths‚Äîincluding the existence of current signs 
and symptoms ‚Äîwill be collected for each body system.  
9.2.5 Use of Medications  
All medications taken by [CONTACT_80968] 30 days 
before enrollment and continuing throughout the study wil l be collected.  All 
medications used will be coded according to the World Health Organization ( WHO) 
drug dictionary.  The number and percentage of participants receiving prior and 
concomitant medications/therapi[INVESTIGATOR_185511]. 
9.[ADDRESS_219075] 30 adult subjects had week 12 C -
peptide data available for the report.  
Immune Tolerance Network  CONFIDENTIAL  Page 61 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   Prior to initiating the study in the pediatric age group (6 -17 years old), adults (18 -45 
years old) were randomized 2:[ADDRESS_219076] disposition, 
early C-peptide levels (baseline through week 12), safety (see Section 9 .2.3), site 
performance, and data quality.  In addition, data will be reviewed by [CONTACT_185553], NIAID medical monitor, 
ITN physician or protocol chairs to warrant review.  
ÔÇ∑ Study-related AEs associated with stoppi[INVESTIGATOR_004] (Section 3.5.2) will be brought 
immediately to the attention of the DSMB.  
ÔÇ∑ SAEs will be reported to the DSMB per Section 8.5 of the protocol.  
9.4   SAMPLE SIZE  
The primary analysis of the primary endpoint will be conducted using data from the 
78 pediatric participants.  This target number was selected with the goal of detecting a 
clinically meaningful improvement of 39% for tocilizumab over placebo.  Power 
estimates associated with these targets are discussed below (see Table 8).  Prior to 
enrolling pediatric subjects, [ADDRESS_219077] estimates used in these calculations are based on data from 104 
control pediatric subjects (aged 6 to 17 years) pooled from 5 new -onset T1DM 
studies.10,11,60-62  At baseline, the mean (SD) for the mean 2 -hour C-peptide equaled 
0.70 (0.312) pmol/ml. Control group estimates for  average change  in the mean 2 -hour 
C-peptide AUC from baseline to Month 12 and the associated root mean square error 
(RMSE) were derived from analysis of covariance models (ANCOVA) using baseline 
AUC as a covaria te.  The average change in the mean 2 -hour C-peptide AUC (RMSE) 
equaled -0.31 (0.221) pmol/ml (i.e. a 44% drop) .  
Under the assumption that these computed values represent the parameters expected 
for the control group and using a 2:1 random assignment of tocilizumab versus 
placebo with a significance level of 5%, a study of [ADDRESS_219078] 80% power to detect a 39% improvement of tocilizumab over controls.  
That is, assuming a control group drop in mean 2 -hour C-peptide AU C of 44% at 
Month 12 (i.e. 0.70 at baseline, 0.39 at Month 12) and a drop of 22% in the 
tocilizumab (i.e. 0.70 at baseline, 0.542 at Month 12), then power equals 80%.  The 
design has 89% power to detect a 44% improvement (i.e. groups differ by 0.17 
pmol/ml).  If the RMSE equals 0.25, which is the upper 90% confidence limit for 
Immune Tolerance Network  CONFIDENTIAL  Page 62 
Protocol ITN058AI: Greenbaum  Version 6.[ADDRESS_219079] a 44% improvement 
drops to 80 %. 
Table 8. Summary of Power/Sample Size Results  for Pediatric Particip ants 
Total 
N mean 
AUC at 
baseline Average 
change in 
mean AUC  
at Month 12: 
placebo Average 
change in 
mean AUC  
at Month 12: 
tocilizumab RMSE Difference 
between groups at 
Month 12 (% 
improvement of 
tocilizumab over 
placebo) % Power 
78 0.70 -0.310 
 (44% drop)  -0.158 
(a 22% drop)  0.22 0.15 (39%)  80% 
78 0.70 -0.310 -0.138 
(a 20% drop)  0.22 0.17 (44%)  89% 
78 0.70 -0.310 -0.138 0.25 0.17 (44%)  80% 
Note:  % improvement of tocilizumab over placebo is computed as: (AUC 12_tocilizumab  ‚Äì 
AUC12_placebo) divided by [CONTACT_12265] 12_placebo. 
9.5 PHARMACOKINETIC ANAL YSES 
All PK analyses will use the actual sampling times.  PK parameters C max (¬µg/mL), tmax 
(h), Cmin (¬µg/mL), AUC 0‚Äì28 d (¬µgÔÉóh/mL) (following the first and last  infusions), and 
AUC 0-t or AUC 0 -‚àû, will be estimated, as data permit.  In addition, terminal phase 
half-life (t1/2,z) and clearance (CL) may also be estimated from the data.  
PK data may be used to explore the exposure -response relationship in T1DM patients.  
9.6 REPORTING DE VIATIONS FROM THE OR IGINAL STATISTICAL 
PLAN 
The principal features of both the study design and the plan for statistical data analysis 
are outlined in this protocol and in the statistical analysis plan (SAP).  Any change in 
these features requires either a protocol or an SAP amendment, which is subj ect to 
review by [CONTACT_4318], the study sponsor(s), and the appropriate H ealth Authorities.  
These changes will be described in the final study report as appropriate.  
10   STUDY  ADMINISTRATION  
10.1 SPONSOR  
This clinical trial is conducted through the NIAID NIH -funded Cooperative 
Agreement awarded to the Benaroya Research Institute at Virginia Mason (Seattle, 
WA) (BRI) to support the Immune Tolerance Network (ITN), a collaborative network 
for clinical research.  The ITN provides financial support for the conduct of the  
Immune Tolerance Network  CONFIDENTIAL  Page 63 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   clinical trial to the clinical sites through subcontracts between the BRI and the clinical 
sites.  The NIAID NIH serves  as the US Sponsor of the Investigational New Drug 
application (IND) for the Protocol and the Global Study Sponsor in Australia 
(represented by [CONTACT_185530], Inc. ([COMPANY_003]) as Local Sponsor in 
Australia) an d is responsible for all regulatory filings and safety reporting.  
10.2 RELATIONSHIP WITH IN DUSTRY  
Tocilizumab provided by [CONTACT_59919] ( Genentech , Inc. a member of  the 
[COMPANY_002] group, South San Francisco, CA ) free of charge will be used in the United 
States for treatment of adult and pediatric participants, and Genentech, Inc. will also 
be providing additional financial support for the conduct of the study.  They will 
receive de -identified samples to conduct mechanistic studies solely as directed by [CONTACT_185554] (DAIT, NIAID , NIH).   
11   ACCESS TO SOURCE DATA/DOCUMENTS  
The investigational sites participating in this study will maintain the highest degre e of 
confidentiality permitted for the clinical and research information obtained from 
participants in this clinical trial.  Medical and research records should be maintained 
at each site in the strictest confidence.  However, as a part of the quality assu rance and 
legal responsibilities of an investigation, the investigational sites must permit 
authorized representatives of the Global Study Sponsor (DAIT, NIAID , NIH); Local 
Sponsor ‚Äì ([COMPANY_003] Australia ), ITN, Genentech, Inc.  (the study drug manufacturer) , and 
the Health Authorities  (US FDA, Australian TGA)  to examine (and to copy when 
required by [CONTACT_1289]) clinical records for the purposes of quality assurance 
reviews, audits, and evaluation of the study safety and progress.  Unless required by 
[CONTACT_185555] p ermitting copying of records, only the coded identity associated with 
documents or other participant data may be copi[INVESTIGATOR_530] (and any personally identifying 
information must be obscured).  Authorized representatives as noted above are bound 
to maintain the stri ct confidentiality of medical and research information that may be 
linked to identified individuals.  The investigational sites will normally be notified in 
advance of auditing visits.  
[ADDRESS_219080] of the 
study is fully documented.  The investigator is required to ensure that all CRFs are 
completed for every participant entered in the trial.  
The Global Study Sponsor ( DAIT, NIAID, NIH)  is responsible for regular inspection 
of the conduct of the trial, for verifying adherence to the protocol, and for confirming 
the completeness, consistency, and accuracy of all documented data.  
The CRFs will be completed online via a web -based electronic data capture (EDC) 
system that has been validated and is compliant with Part 11 Title 21 of the U.S. Code 
Immune Tolerance Network  CONFIDENTIAL  Page 64 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   of Federal Regulations .  Study staff at the site will enter information into the 
electronic CRFs, and the data will be stored remotely at a central database .  Data 
quality will be ensured through the EDC system‚Äôs continuous monitoring of data and 
real-time detection and correction of errors.  All elements of data entry (i.e., time, 
date, verbatim text, and the name [CONTACT_185559] g the data entry) will be 
recorded in an electronic audit trail to allow all changes in the database to be 
monitored and maintained in accordance with federal regulations.   
13 ETHICAL CONSIDERATIONS AND COMPLIANCE WITH GOOD CLINICAL 
PRACTICE  
13.1 STATEMENT OF COMP LIANCE  
This trial will be conducted in compliance with the protocol, current Good Clinical 
Practice (GCP)  guidelines ‚Äîadopting the principles of the Declaration of Helsinki ‚Äî
and all applicable regulatory requirements.  
Prior to study initiation, the protocol and the informed consent documents will be 
reviewed and approved by [CONTACT_185556]  (IRB/EC).  Any amendments to the protocol or 
consent materials must also be approved by [CONTACT_185557] y Sponsor ( DAIT, NIAID, 
NIH) and the sponsor representative ([COMPANY_003] Australia),  the IRB/EC and submitted to 
the appropriate Health Authorities  before they are implemented.  
13.2 INFORMED CONSENT  
The informed consent form is a means of providing information about th e trial to a 
prospective participant and allows for an informed decision about participation in the 
study.  All participants (or their legally acceptable representative) must read, sign, and 
date a consent form before participating in the study, taking the  study drug, and/or 
undergoing any study -specific procedures.   
The informed consent form must be updated or revised whenever important new 
safety information is available, whenever the protocol is amended, and/or whenever 
any new information becomes avail able that may affect participation in the trial.  
A copy of the informed consent will be given to a prospective participant for review.  
The attending health care provider  will review the consent and answer questions.  The 
participant  will be informed that participation is voluntary and that he/she may 
withdraw from the study at any time, for any reason.   Assent will also be obtained 
from children with due consideration for age appropriate private conversations 
between study health car e provider and participant.  
Immune Tolerance Network  CONFIDENTIAL  Page 65 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   13.3 PRIVACY AND CONFIDEN TIALITY  
A participant‚Äôs privacy and confidentiality will be respected throughout the study.  
Each participant will be assigned a sequential identification number.  This number, 
rather than the participant‚Äôs n ame, will be used to collect, store, and report participant 
information.  
14   PUBLICATION POLICY 
The ITN policy on publication of study results will apply to this study.  Authorized 
participants may find details regarding the policy statement on the ITN inter net 
website   As a jointly sponsored study with Type I 
Diabetes TrialNet , publications will also comply with TrialNet publications policy and 
procedures  
15   REFERENCES  
1. Type 1 Diabetes, 2010; Prime Group for JDRF, Mar 2011. 2010.  
2. Shrestha SS, Zhang P, Albright A, Imperator e G. Medical expenditures associated with 
diabetes among privately insured U.S. youth in 2007. Diabetes Care. 2011;34(5):1097 -1101. 
3. Gregg EW, Li Y, Wang J, et al. Changes in diabetes -related complications in the [LOCATION_002], 
1990-2010. The New England Journal of Medicine. 2014;370(16):[ADDRESS_219081] youth with type 1 diabetes in the T1D Exchange 
Clinic Registry do not meet American Diabetes Association or International Society for 
Pediatric and Ad olescent Diabetes clinical guidelines. Diabetes care. 2013;36(7):[ADDRESS_219082] WV, Bergenstal RM, Miller KM, DuBose SN, Hall CA. The T1D 
Exchange clinic registry. Journal of Clinical Endocrinology & Metabolism. 2012;97(12):4383 -
4389. 
6. Weinstock RS, Xing D, Maahs DM, et al. Severe hypoglycemia and diabetic ketoacidosis in 
adults with type 1 diabetes: results from the T1D Exchange clinic registry. Journal of Clinical 
Endocrinology & Metabolism. 2013;98(8):3411 -3419. 
7. Simmons JH, Chen V, Miller KM, et al. Differences in the management of type 1 diabetes 
among adults under excellent control compared with those under poor control in the T1D 
Exchange Clinic Registry. Diabetes care. 2013;36(11):3573 -3577. 
8. Trief PM, Xing D, Foster NC, et al. Depression in Adults in the T1D Exchange Clinic 
Registry. Diabetes care. 2014;37(6):1563 -1572. 
9. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti -CD3 monoclonal 
antibody hOKT3gamma1(Ala -Ala) results in improvement i n C-peptide responses and clinical 
parameters for at least 2 years after onset of type 1 diabetes. Diabetes. 2005;54(6):1763 -1769. 
10. Pescovitz MD, Greenbaum CJ, Krause -Steinrauf H, et al. Rituximab, B -lymphocyte depletion, 
and preservation of beta -cell function. N Engl J Med. 2009;361(22):2143 -2152. 
11. Orban T, Bundy B, Becker DJ, et al. Co -stimulation modulation with abatacept in patients with 
recent-onset type 1 diabetes: a randomised, double -blind, placebo -controlled trial. Lancet. 
2011;378(9789):412 -419. 
12. Gallagher MP, Goland RS, Greenbaum CJ. Making progress: preserving beta cells in type 1 
diabetes. Ann N Y Acad Sci. 2011;1243:[ADDRESS_219083] of intensive treatment of diabetes on the development and progression of long -term 
complications in insulin -dependent diabetes mellitus. The Diabetes Control and Complications 
Trial Research Group. N Engl J Med. 1993;329(14):977 -986. 
14. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular 
disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643 -2653. 

Immune Tolerance Network  CONFIDENTIAL  Page 66 
Protocol ITN058AI: Greenbaum  Version 6.[ADDRESS_219084] GG, Gyurus E, Green A, Soltesz G. Incidence trends for childhood 
type 1 diabetes in Europe during 1989 -2003 and predicted new cases 2005 -20: a multicentre 
prospective regist ration study. Lancet. 2009;373(9680):2027 -2033. 
16. Davis A, et al. Residual C -Peptide in Patients 3 -81 Years from Diagnosis of T1D: A T1D 
Exchange Study. General Poster Session presented at American Diabetes Association, 
Chicago, IL. 2013. 
17. Greenbaum C J, Beam CA, Boulware D, et al. Fall in C -peptide during first 2 years from 
diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet 
data. Diabetes. 2012;61(8):2066 -2073. 
18. Karjalainen J, Salmela P, Ilonen J, Surcel HM, Knip M. A comparison of childhood and adult 
type I diabetes mellitus. N Engl J Med. 1989;320(14):[ADDRESS_219085] year of disease in children an d adolescents with Type 1 diabetes 
mellitus. Diabetic Medicine : A Journal of the British Diabetic Association. 1998;15(10):844 -
850. 
20. Marzelli MJ, Mazaika PK, Barnea -Goraly N, et al. Neuroanatomical correlates of dysglycemia 
in young children with type 1 diabetes. Diabetes. 2014;63(1):343 -353. 
21. Samson M, Audia S, Janikashvili N, et al. Brief report: inhibition of interleukin -6 function 
corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis and 
rheumatism. 2012;64(8):2499 -2503. 
22. Liu SM, Lee DH, Sullivan JM, et al. Differential IL -21 signaling in APCs leads to disparate 
Th17 differentiation in diabetes -susceptible NOD and diabetes -resistant NOD.Idd3 mice. The 
Journal of clinical investigation. 2011;121(11):4303 -4310. 
23. Campbell IL, Kay TW, Oxbrow L, Harrison LC. Essential role for interferon -gamma and 
interleukin -6 in autoimmune insulin -dependent diabetes in NOD/Wehi mice. The Journal of 
clinical investigation. 1991;87(2):739 -742. 
24. Schneider A, Rieck M, Sanda S, Pi[INVESTIGATOR_92746]  C, Greenbaum C, Buckner JH. The effector T cells of 
diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. Journal of 
Immunology. 2008;181(10):7350 -7355. 
25. Ferreira RC, Freitag DF, Cutler AJ, et al. Functional IL6R 358Ala alle le impairs classical IL -6 
receptor signaling and influences risk of diverse inflammatory diseases. PLoS genetics. 
2013;9(4):e1003444.  
26. Arif S, Moore F, Marks K, et al. Peripheral and islet interleukin -[ADDRESS_219086] activation 
characterizes human autoimmune  diabetes and promotes cytokine -mediated beta -cell death. 
Diabetes. 2011;60(8):2112 -2119. 
27. Ferraro A, Socci C, Stabilini A, et al. Expansion of Th17 cells and functional defects in T 
regulatory cells are key features of the pancreatic lymph nodes in pat ients with type 1 diabetes. 
Diabetes. 2011;60(11):2903 -2913. 
28. Marwaha AK, Leung NJ, McMurchy AN, Levings MK. TH17 Cells in Autoimmunity and 
Immunodeficiency: Protective or Pathogenic? Front Immunol. 2012;3:129.  
29. Boe A, Baiocchi M, Carbonatto M, Papoi an R, Serlupi -Crescenzi O. Interleukin 6 knock -out 
mice are resistant to antigen -induced experimental arthritis. Cytokine. 1999;11(12):1057 -1064. 
30. Alonzi T, Fattori E, Lazzaro D, et al. Interleukin 6 is required for the development of collagen -
induced a rthritis. J Exp Med. 1998;187(4):461 -468. 
31. Sasai M, Saeki Y, Ohshima S, et al. Delayed onset and reduced severity of collagen -induced 
arthritis in interleukin -6-deficient mice. Arthritis Rheum. 1999;42(8):1635 -1643. 
32. Takagi N, Mihara M, Moriya Y, et al. Blockage of interleukin -6 receptor ameliorates joint 
disease in murine collagen -induced arthritis. Arthritis Rheum. 1998;41(12):[ADDRESS_219087] apoptosis in chronic intestinal inflammation: evidence in crohn disease and 
experimental colitis in vivo. Nature medicine. 2000;6(5):583 -588. 
Immune Tolerance Network  CONFIDENTIAL  Page 67 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   34. Yamamoto M, Yoshizaki K, Kishimoto T, Ito H. IL -6 is required for the development of Th1 
cell-mediated murine colitis. J Immunol. 2000;164(9):4878 -4882. 
35. Mudter J, Neurath MF. Il -6 signaling in inflammatory bowel disease: pathophysiological role 
and clinical relevance. Inflammatory Bowel Diseases. 2007;13(8):1016 -1023. 
36. Firestein GS, Alvaro -Gracia JM, Maki R. Quantitative analysis of cytokine gene expression in 
rheumatoid arthritis. Journal of Immunology. 1990;144(9):[ADDRESS_219088] -Akrad M, Witzmann G, et al. Cytokine production by [CONTACT_185558] T cells in 
rheumatoid arthritis. Rheumatology(Oxford). 1999;38(3):202 -213. 
38. Hyams JS, Fitzgerald JE, Treem WR, Wyzga N, Kreutzer DL. Relationship of functional and 
antigenic interleukin 6 to disease activity in inflammatory bowel disease. Gastroenterology. 
1993;104(5):[ADDRESS_219089] of interleukin -6 receptor inhibition with 
tocilizumab in patients with rheumatoid arthritis (OPTION study): a double -blind, placebo -
controlled, randomised trial. Lancet. 2008;371(9617 ):987-997. 
40. Emery P, Keystone E, Tony HP, et al. IL -6 receptor inhibition with tocilizumab improves 
treatment outcomes in patients with rheumatoid arthritis refractory to anti -tumour necrosis 
factor biologicals: results from a 24 -week multicentre random ised placebo -controlled trial. Ann 
Rheum Dis. 2008;67(11):1516 -1523. 
41. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with 
systemic-onset juvenile idiopathic arthritis: a randomised, double -blind, placebo -controlled, 
withdrawal phase III trial. Lancet. 2008;371(9617):998 -1006. 
42. Tanaka T, Narazaki M, Kishimoto T. Therapeutic targeting of the interleukin -6 receptor. Annu 
Rev Pharmacol Toxicol. 2012;52:199 -219. 
43. Schultz O, Oberhauser F, Saech J, et al. Effects of inh ibition of interleukin -6 signalling on 
insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PloS 
one. 2010;5(12):e14328.  
44. Hingorani AD, Casas JP. The interleukin -6 receptor as a target for prevention of coronary hea rt 
disease: a mendelian randomisation analysis. Lancet. 2012;379(9822):1214 -1224. 
45. Brunner H, Ruperto N, Zuber Z, et al. Efficacy and Safety of Tocilizumab in Patients with 
Polyarticular Juvenile Idiopathic Arthritis: Data From a Phase 3 Trial. Paper pr esented at: 
American College of Rheumatology2012; Washington, DC.  
46. De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic 
juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385 -2395. 
47. De Benedetti F, Brunner H, Ruperto N, et al. Catch -up growth during tocilizumab therapy for 
systemic juvenile idiopathic arthritis: results from a phase III trial. Arthritis Rheumatol. 
2015;67(3):840 -848. 
48. Yokota S, Imagawa T, Mori M, et al. Longterm sa fety and effectiveness of the anti -interleukin 
6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic 
arthritis in Japan. J Rheumatol. 2014;41(4):759 -767. 
49. Aoki C, Inaba Y, Choe H, et al. Discrepancy between clinical an d radiological responses to 
tocilizumab treatment in patients with systemic -onset juvenile idiopathic arthritis. J 
Rheumatol. 2014;41(6):1171 -1177. 
50. Brunner HI, Ruperto N, Zuber Z, et al. Efficacy and safety of tocilizumab in patients with 
polyarticular -course juvenile idiopathic arthritis: results from a phase 3, randomised, double -
blind withdrawal trial. Ann Rheum Dis. 2015;74(6):[ADDRESS_219090] 3, 2011.  
http://www.roche.com/media/store/releases/med -cor-2011-08-03.htm.  
52. Zgibor JC, Songer TJ, Kelsey SF, Drash AL, Orchard TJ. Influence of health care providers on 
the development of diabetes complications: long -term follow -up from the Pi[INVESTIGATOR_185512]. Diabetes care. 2002;25(9):1584 ‚Äì1590. 
53. Nathan DM, Lachin J, Cleary P, et al. Intensive diabetes therapy and carotid intima -media 
thickness in type 1 diabetes mellitus. N Engl J Med. 2003;348(23):2294 -2303. 
Immune Tolerance Network  CONFIDENTIAL  Page 68 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   54. Nathan DM, Zinman B, Cleary PA, et al. Modern -day clinical course of type 1 diabetes 
mellitus after 30 years' duration: the diabetes control and complications trial/epi[INVESTIGATOR_185513] (1983 -2005). Arch Intern Med. 2009;169(14):[ADDRESS_219091] of intensive therapy on the risk of 
retinopathy complications in patients with type 1 diabetes mellitus: 1 0 years after the Diabetes 
Control and Complications Trial. Arch Ophthalmol. 2008;126(12):1707 -1715. 
56. Effects of age, duration and treatment of insulin -dependent diabetes mellitus on residual beta -
cell function: observations during eligibility testing f or the Diabetes Control and 
Complications Trial (DCCT). The DCCT Research Group. The Journal of clinical 
endocrinology and metabolism. 1987;65(1):[ADDRESS_219092] of intensive therapy on residual beta -cell function in patients with type 1 diabetes in the 
diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control 
and Complications Trial Research Group. Ann Intern Med. 1998;128(7):517 -523. 
58. Montanya E, Fernandez -Castaner M, Soler J. Improved metabolic control preserved beta-cell 
function two years after diagnosis of insulin -dependent diabetes mellitus. Diabetes 
Metabolism. 1997;23(4):314 -319. 
59. Steffes MW, Sibley S, Jackson M, Thomas W. Beta -cell function and the development of 
diabetes-related complications in the dia betes control and complications trial. Diabetes care. 
2003;26(3):832 -836. 
60. Wherrett DK, Bundy B, Becker DJ, et al. Antigen -based therapy with glutamic acid 
decarboxylase (GAD) vaccine in patients with recent -onset type 1 diabetes: a randomised 
double-blind trial. Lancet. 2011;378(9788):319 -327. 
61. Gottlieb PA, Quinlan S, Krause -Steinrauf H, et al. Failure to preserve beta -cell function with 
mycophenolate mofetil and daclizumab combined therapy in patients with new - onset type 1 
diabetes. Diabetes care. 2010;33(4):826 -832. 
62. Moran A, Bundy B, Becker DJ, et al. Interleukin -1 antagonism in type 1 diabetes of recent 
onset: two multicentre, randomised, double -blind, placebo -controlled trials. Lancet. 
2013;381(9881):1905 -1915. 
  
Immune Tolerance Network  CONFIDENTIAL  Page 69 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   APPENDIX 1. SCHEDULE OF EVENTS1 
Phase of Trial  Dosing Follow Up  Unsch. 
Week -1 0 4 8 12 16 20 24 39 52 78 104 U 
Visit  V-1 V0 V1 V2 V3 V4 V5 V6 V7 V8 V9 V102 U3 
GENERAL ASSESSMENTS  
Informed consent  X                        
Eligibility criteria  X                        
Randomization    X                      
Medical history  X                        
Adverse events  X X X X X X X X X X X X X 
Concomitant 
medications  X X X X X X X X X X X X X 
Comprehensive 
physical 
examination  X             X4   X   X  
Directed physical 
examination    X4 X4 X4 X4 X4 X4   X   X   X 
Additional vital 
signs (during 
infusion)  X X X X X X X      
CENTRAL LABORATORY ASSESSMENTS  
Serum Chemistries 
(includes liver 
panel and CRP)  X X X X X X X X X X X X X 
Hematology  X X X X X X X X X X X X X 
Urinalysis  X X X X X X X X X X X X X 
Lipid Panel  X   X         X   X X X X 
Viral load (PCR)5 X X X X X X X X X X X X X 
Infectious disease 
serology5 X             
Serum √üHCG6 X             
QuantiFERON TB 
test7 X                   
LOCAL LABORATORY ASSESSMENTS  
Urine HCG6   X X X X X X X X X X X X 
TB test7 X             
                                                           
 
1 With approval of study sponsor (DAIT, NIAID) and after informed consen t, study procedures and/or sample collections may be 
performed at  a location convenient for the participant  as described in the Manual of Operations (MOP) . 
[ADDRESS_219093] ed for this visit (see sections 4.3 and 5.3).  
3 Assessments for unscheduled visits will be at the discretion of the principal investigator.  
4 Physical exam should be conducted prior to study drug administration.  
5 Serology will be repeated after screening  for CMV and EBV if participants show clinical signs of infection; or if viral load 
testing shows that the EBV viral load is ‚â• 10,000 copi[INVESTIGATOR_66487] 106 PBMCs or ‚â• 2,000 copi[INVESTIGATOR_185514] ‚â• 10,[ADDRESS_219094].  
Immune Tolerance Network  CONFIDENTIAL  Page 70 
Protocol ITN058AI: Greenbaum  Version 6.0  June 13, 2018 
TCZ in New -onset T1D   Phase of Trial  Dosing Follow Up  Unsch. 
Week -1 0 4 8 12 16 20 24 39 52 78 104 U 
Visit  V-1 V0 V1 V2 V3 V4 V5 V6 V7 V8 V9 V102 U3 
DISEASE -SPECIFIC ASSESMENTS  
2-Hour MMTT8         X     X X   X   
4-Hour MMTT9 X         X  X  
FSIVGTT10  X      X  X    
Diabetes-related 
autoantibodies  X             
HbA1c X X X X X X X X X X X X  
Glucometer 
Readings X X X X X X X X X X X X  
CGM Readings11  X   X   X  X X X  
Insulin use  X X X X X X X X X X X X  
Hypoglycemic 
events X X X X X X X X X X X X  
STUDY DRUG ADMINISTRATION AND DRUG -RELATED ASSESSMENTS  
Study drug 
infusion   X X X X X X X          
Pharmacokinetics 
(PK)   X12 X13    X12 X13      
IL-6 and IL-6sR X    X   X X X X X  
Anti-TCZ 
antibodies14 X             
MECHANISTIC ASSESSMENTS15 
Serum  X X X X X X X X   X X  X  
Cellular Assays    X X X X X X X   X   X  
Gene Expression    X     X     X   X   X  
DNA    X     X     X   X   X  
 
                                                           
 
8 A 2-hour MMTT is to be performed at weeks 12, 24, 39, and 78.  MMTT should be perf ormed prior to study drug infusion for  
weeks 12 and 24.  
9 A 4-hour MMTT is to be performed at weeks -1 (screening), 52, and 104 for subjects ‚â•12 years old (for subjects <12 years old, 
a 2-hour MMTT will be performed instead).   
10 FSIVGTT will be offered to  subjects age  ‚â•15.  Week [ADDRESS_219095] infusion or within 2 
weeks prior to week 0.  Week 24 and week 52 visits will be done on a separate day than the MMTT visits; the window for these 
two visits are +/ - 2 weeks of t arget date.   
11 Randomized participants will be invited to use a commercially available FDA approved CGM system and its components for a 
14 day period at weeks 0, 12, 24, 52, 78, and 104; the window for the CGM will be ¬± 3 weeks.  Participants may repeat t he 14 
day period once during these widows if less than 10 days of data  is evaluable from initial wear ing.   
12 Pharmacokinetics (PK) samples for week 0 and week 20 will be collected before, 10 minutes after, and 7 (¬±3) days after the 
infusions (see section 6.6). 
13 Pharmacokinetics (PK) samples for week 4 and week 24 will be collected before the infusions (see section 6.6). 
14 Baseline anti -TCZ antibodies samples will be collected for all participants and will only be analyzed in event of specified 
adverse event ( defined as anaphylaxis, serious hypersensitivity, or study treatment discontinuation due to hypersensitivity, 
whether serious or non -serious).  A dditional anti-TCZ antibodies samples will be collected at the time of an adverse event and 
then again at least  [ADDRESS_219096]‚Äôs age and body weight per country specific requirements.  